The relevance of clinical audit results to commissioning services by Davis, H et al.
S1
Available online  http://breast-cancer-research.com/supplements/6/S1
Abstracts from Symposium Mammographicum 2004
Edinburgh International Conference Centre, 19–20 July 2004
1 Developing new treatments for breast cancer
D Lane
University of Dundee, UK and Cyclacel Ltd, UK
Breast Cancer Res 2004, 6(Suppl 1):P1 (DOI 10.1186/bcr820)
Twenty-five years after its first description the p53 protein has
been shown to play a key role in both cancer and ageing. The p53
protein is activated by many different stress pathways, including
oncogene action and DNA damage. The elucidation of the p53
response, which is aberrant in most cancers (including breast,
lung, stomach and colorectal cancer), has provided many new
targets for drug development and p53 gene therapy is now
approved in China. In tumours where p53 is mutant small
molecules may be able to restore its function. In many tumours the
wild-type p53 gene remains intact but its function is compromised
by loss of upstream signalling pathways or downstream effectors.
A key regulator is Mdm2, an E3 ubiquitin ligase, that binds and
ubiquitinates p53 and directs its degradation via the proteosome.
Small potent peptides that can block the p53 Mdm2 interaction
and activate the p53 response have been described. Growing
selections of lead small molecules that mimic the action of these
peptides have also been recently discovered. Cell-based screens
have revealed that inhibitors of nuclear export and inhibitors of
transcription (one of which is in clinical trial) can also activate the
p53 response therapeutically. The pharmaceutical regulation of
the p53 pathway offers great hope for improved treatment of
human cancer.
2 Mammographic screening with a breast cancer prevention programme
P Boyle
Director, International Agency for Research on Cancer, Lyon, France
Breast Cancer Res 2004, 6(Suppl 1):P2 (DOI 10.1186/bcr821)
3 Sonographic evaluation of solid breast nodules
T Stavros
University of Colorado, Denver, USA
Breast Cancer Res 2004, 6(Suppl 1):P3 (DOI 10.1186/bcr822)
Because of the heterogeneity of breast cancer from nodule to
nodule, single findings cannot achieve the sensitivity or the
negative predictive value necessary to identify a low-risk group
that can be offered the option of follow-up (ACR Breast
Imaging Reporting and Data System [BIRADS] 3 group).
However, by using multiple findings in a strict algorithm, such a
group can be identified. It is also important to keep in mind that
breast cancer can be heterogeneous within an individual
nodule. Part of the nodule may have circumscribed features
that simulate a benign lesion, while another part may be
spiculated and obviously malignant. Only by scanning the
whole surface and substance of the nodule in two orthogonal
planes (radial and anti-radial) can the presence of suspicious
findings be excluded, and if there is a mixture of benign and
suspicious findings, the benign findings should be ignored.
These studies show that sonography is useful in the
characterization of solid breast masses. Characterizing solid
breast nodules into BIRADS categories defines carcinomas
that might have been missed clinically or mammographically. It
identifies a BIRADS 3 group that has far less than 2% risk of
being malignant and can offer the patient the option of follow-
up rather than biopsy. Currently, approximately 80% of patients
with BIRADS 3 solid nodules are electing to be followed rather
than to undergo biopsy. It improves the accuracy of the
diagnosis of malignant breast lesions. Importantly, it also
accurately defines a population of benign solid breast lesions
that do not require biopsy when strict sonographic criteria of
benignity are present.
To achieve the desired sensitivity and negative predictive
values of 98% or greater the algorithm must be strictly adhered
to. When the patient elects to be followed rather than undergo
biopsy, follow-up should be performed in 6 months, not 1 year.
The malignant lesions at most risk to be mischaracterized as
BIRADS 3 are higher grade invasive ductal carcinomas that
grow rapidly enough for change to be readily detected at
6 months.S2
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Table 1
Current study: characterization of solid breast nodules
Benign histology Malignant histology All biopsies
Negative US (BIRADS 2, 3) 245 (true negatives) 1 (false negatives) 246
Positive US (BIRADS 4a, 4b, 5) 559 (false positives) 406 (true positives) 965
Total 804 407 1211
Sensitivity = 406/407 = 99.8%. Negative predictive value = 245/246 = 99.6%. Specificity = 245/804 = 30.5%. Positive predictive value =
406/965 = 42.1%. Accuracy = (245 + 406)/1211 = 53.8%.
Table 2
Prospective characterization of 1211 solid nodules into BIRADS categories (all 1211 nodules have undergone biopsy)
Number of  Number of  Expected risk  Actual risk 
BIRADS category nodules biopsied malignant nodules of cancer (%) of cancer (%)
21 5 0 0 0
3 231 1 ≤ 2 0.4
4a 515 52 3–49 10
4b 191 118 50–89 62
5 259 236 ≥ 90 91
Total 1211 407 34
4 Patient safety: why do things go wrong?
R Flin
Industrial Psychology Research Centre and Patient Safety Research Group, University of Aberdeen, UK
Breast Cancer Res 2004, 6(Suppl 1):P4 (DOI 10.1186/bcr823)
Concern over the levels of patient safety within hospitals was
raised following a series of studies showing unacceptable rates
(3–17% of admissions) of adverse events (injury to patients).
Government health agencies acknowledged that the standard
of safety for patients was unacceptable and that healthcare
providers would be required to tackle this issue. Other
industries, particularly in the more hazardous sectors such as
energy production, take a very systematic approach to
managing safety. They have realized that human factors play a
major contributing role to accident causation, but that this
encompasses not just the humans operating the system, but
also the humans who are managing the organization. Leape
and colleagues [1] argued that many hospital systems are
designed to rely on the error-free performance of individuals,
whereas in industry it is appreciated that human error is
inevitable and that accidents occur due to both human failures
and latent conditions. Both are influenced by the underlying
safety culture of the organisation (e.g. level of management
commitment to safety). Drawing on psychological research into
safety management in high-risk industries, this paper examines
three techniques used to diagnose the state of safety:
measuring safety climate; assessing senior managers’
commitment to safety; and evaluating nontechnical skills for
safety critical positions.
Reference
1. Leape L, Woods D, Hatlie M, Kizer K, Schroeder S, Lundberg G:
Promoting patient safety by preventing medical error. J Am Med
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5 Critical incident reporting in the National Health Service breast units
S Barter, P Britton
Cambridge Breast Unit, Addenbrooke’s Hospital, Cambridge, UK
Breast Cancer Res 2004, 6(Suppl 1):P5 (DOI 10.1186/bcr824)
The Royal College of Radiologists (RCR) Breast Group has
recently launched a Critical Incident reporting scheme. The aim
is to collect data on adverse events specific to breast imaging
in the hope of alerting units to potential hazards and incidents
in a timely fashion (rather than reading about them in the
newspapers!). Critical Incident reports can be submitted onlineS3
(http://www.rcrbreastgroup.com) or in paper form using either
the RCR Breast Group or local incident form. This is not intended
to replace the national scheme for reporting being developed by
the National Patient Safety Association. Events collected to date
already reveal common themes such as mistakes surrounding
biopsy specimen handling and patient identification.
6 Biopsied in the USA
R Davies
Breast Care Unit, Royal Devon and Exeter Hospital, Exeter, UK
Breast Cancer Res 2004, 6(Suppl 1):P6 (DOI 10.1186/bcr825)
Fine needle aspirate and core biopsy are well established
techniques in the UK for achieving preoperative diagnoses for
palpable and impalpable breast lesions. Since the mid-1990s
the number of units using Mammotome has steadily increased;
as yet no randomised trial comparing vacuum-assisted biopsy
against automated core biopsy has been published. However,
a critical review of currently available literature has shown a
significant decrease in the high-risk lesion underestimate rate
and a nonsignificant decrease in the ductal carcinoma in situ
underestimate rate when compared with published data on
14 G core biopsy [1]. The aim of this bursary was to visit two
centres in the US and briefly review the next generation of ‘post
mammotome’ biopsy devices that are in routine use and likely
to be launched in the UK. As none of these devices have been
subject to a randomised trial this report is a subjective
evaluation of these techniques by a UK practitioner working in
the National Health Service Breast Screening Programme and
Symptomatic Breast Imaging service.
Reference
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7 The impact of mammographic screening on breast cancer mortality: overview of the evidence so
far
R Gabe1, SW Duffy2
1Cancer Research UK, London, UK; 2Queen Mary University of London, UK
Breast Cancer Res 2004, 6(Suppl 1):P7 (DOI 10.1186/bcr826)
Controversy remains over the scale of benefit women can
expect from attending mammographic screening programs. We
review the evidence, presenting (1) an updated meta-analysis
of the latest results from the randomised trials and (2) an
overview of the non-randomised evidence.
After eight randomised trials with 12–20 years follow-up, the
pooled results show a significant 20% (95% confidence interval
[CI]: 14%, 27%) reduction in breast cancer mortality associated
with invitation to screening. When stratified by age, the
reductions were 15% (95% CI: 2%, 27%) for women aged
under 50 and 22% (95% CI: 14%, 30%) for women aged
50–74.
The search strategy for nonrandomised evidence relating to
mortality yielded 12 descriptive studies, seven case-series, six
case–control, eight cohort and three nonrandomised
comparative studies. All indicated some benefit associated
with screening. Overall, the case–control studies indicated a
35% (95% CI: 20%, 48%) reduction in breast cancer mortality
associated with screening. The corresponding reduction for
cohort studies was 44% (95% CI: 39%, 48%) for screening
and 31% (95% CI: 21%, 40%) for invitation.
The majority of evidence from randomised and nonrandomised
sources demonstrates a reduction in breast cancer mortality
with screening. Studies should continue to monitor the benefit
of screening programmes, taking care to address potential
forms of bias.
8 A case–control study to estimate the impact on breast cancer death of the breast screening
programme in Wales
HM Fielder1, D Brook1, J Cuzick2, J Warwick2, SW Duffy2
1Breast Test Wales, Cardiff, UK; 2CR-UK/Wolfson Institute of Preventive Medicine, London, UK
Breast Cancer Res 2004, 6(Suppl 1):P8 (DOI 10.1186/bcr827)
We set up a case–control study to estimate the effect of
service screening, as provided by the National Health Service
breast screening programme, on breast cancer mortality in
Wales. The basic design was a case–control study with 1:2
matching using data recorded by Breast Test Wales. The
cases are deaths from breast cancer in women aged
50–75 years, diagnosed after the instigation of screening in
1991 and at age 50 or over. The controls are women who have
not died of breast cancer, matched by risk set and year of birth.
We recruited 436 cases and 750 controls.
The odds ratio for risk of death from breast cancer for women
who have attended at least one routine screen compared with
those never screened was 0.62 (confidence interval:
Available online  http://breast-cancer-research.com/supplements/6/S1S4
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0.47–0.81), which suggests a reduction in risk of 38%, and no
smaller than 19%. After correcting for anticonservative and
conservative biases, the estimated mortality reduction was
25% (odds ratio = 0.75; 95% confidence interval: 0.49, 1.14;
P = 0.09).
This study suggests that the Breast Test Wales screening
programme is achieving a 25–38% reduction in breast cancer
mortality in women attending for screening, consistent with the
results of the randomized controlled trials of mammographic
screening.
9 Quality management: the key to achievement for the BreastScreen Australia Programme
J Muller
Australian Institute of Health and Welfare, Canberra, Australia and BreastScreen Australia State and Territory Programmes,
Brisbane, Australia
Breast Cancer Res 2004, 6(Suppl 1):P9 (DOI 10.1186/bcr828)
The BreastScreen Australia Programme commenced in 1991.
Since then a national network of breast cancer screening
services has been established.
The Programme is underpinned by a quality management
infrastructure with national and State/Territory roles and
responsibilities. All BreastScreen Australia services must
comply with National Accreditation Standards. To monitor
quality at the service, State and National level, all services
collect the National Minimum Dataset using the National Data
Dictionary. Monitoring and Evaluation Plans are being
implemented with annual reporting undertaken by the
Australian Institute of Health and Welfare. A key evaluation
project commissioned by the Programme is the mortality study.
During the period 1996–2001 BreastScreen Australia screened
over 4.5 million women, and has consistently maintained cancer
detection rates and detection rates for small cancers at or above
minimum standards set for services to achieve.
Since the commencement of the BreastScreen Australia
Programme there has been a 23.7% reduction in the death rate
from breast cancer in women aged 50–69 years. The 5-year
survival rate after diagnosis from breast cancer increased from
72.3% during 1982–1986 to 84% between 1992 and 1997.
This presentation will outline of the quality management
infrastructure and key achievements of BreastScreen Australia.
Reference
BreastScreen Australia Monitoring Report 2000–2001. Canberra:
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10 Breast screening radiographers and radiologists: performance and confidence levels on the
PERFORMS film sets
HJ Scott, AG Gale, CE Griffiths
University of Derby, UK
Breast Cancer Res 2004, 6(Suppl 1):P10 (DOI 10.1186/bcr829)
Specially trained radiographers are increasingly double-reading
screening cases with radiologists. Each year the majority of these
film-readers interpret a ‘PERFORMS’ set of difficult cases as a
means of self-assessing their skills. We examined the
radiographers’ confidence in their interpretation of these difficult
cases and investigated whether they performed as well as
radiologists. We also studied radiographers’ performance and
confidence ratings over a number of years, comparing those with
different levels of experience. Additionally, by closely matching
individual radiographers and radiologists, we investigated real-life
experience, performance and confidence levels on PERFORMS,
fractionating by both volume of cases read, and years of
experience. Data were examined for approximately 250 breast-
screening radiologists and 90 specially trained radiographers
over 3 years. Overall, radiographers did not perform as well as
radiologists on this particular task, nor were they as confident of
their diagnosis. However, when closely matched on real-life
factors these differences in performance levels disappeared and
radiographers performed as well as radiologists. Although the
more experienced radiographers performed at a level similar to
the radiologists, differences in confidence levels remained. This
supports the current UK practice of radiographers double-
reading with radiologists and implies that experienced
radiographers, like radiologists, may be able to be single-readers.
11 A 3-year audit of radiographer screen film reading
AE Hubbard1,2, SL Lawson1,2, SC Duthie1,2, RL Tetlow1,2, C Bradley1,2, E Dean1,2
1Hull and East Yorkshire NHS Trust, Hull, UK; 2 Humberside BreastScreening Programme, Hull, UK
Breast Cancer Res 2004, 6(Suppl 1):P11 (DOI 10.1186/bcr830)
A team of five radiographers assists with film reading in our
large combined screening and symptomatic breast unit. The first
were trained in 1999, and now have 5 years experience. For
the last 3 years their screen reading performance has been
intensively audited.S5
Film reading numbers have ranged from 4.8 to 11,000/year.
Cancer detection rates average 6/1000, with the best
radiographer achieving 7/1000. Recall rates are kept low by
consensus review of all recalls, less than 5%.
Film reading performance in real life does reflect the
‘PERFORMS’ score.
Lobular cancers are more likely to be missed by new film
readers and are disproportionately over-represented in the
‘minority report’ cancers detected.
In conclusion, radiographers perform as well as average breast-
screening radiologists after 3 years supervised experience.
12 Determinants of false positive recall rates in an Australian mammographic screening programme
AM Kavanagh1, D Jolley2, A Chapman3, A Amos1, JN Cawson4, N Davidson3, L Heuzenroeder3, DM Gertig5, J Evans6
1BreastScreen Victoria, Melbourne, Australia; 2Deakin University, Melbourne, Australia; 3Department of Human Services and
Health, Melbourne, Australia; 4St Vincents BreastScreen, Melbourne, Australia; 5University of Melbourne, Australia; 6Monash
BreastScreen, Australia
Breast Cancer Res 2004, 6(Suppl 1):P12 (DOI 10.1186/bcr831)
We assessed the clinical and service related determinants of
false positive recall using a case–control study of women who
attended BreastScreen Victoria between 1994 and 1999.
Cases were randomly selected from all women who were
recalled for assessment but did not have cancer (false
positives), and controls were selected from women who had a
negative assessment and did not have cancer. Separate
analyses were conducted for first (n = 12,667) and
subsequent rounds (n = 17,461).
To identify reader characteristics associated with false positive
recall we conducted generalised linear modeling of all women
who attended between 1994 and 1999.
In the case–control study year of screen, strong family history
and age at screening were important predictors of false
positive recall at first round. At subsequent rounds, age, time
since introduction of Kodak MIN-R-2000 film, strong family
history of breast cancer, hormone replacement therapy use,
recall at previous screen, previous screen at more than
27 months and screening round were significant predictors.
In the analysis of reader characteristics, false positive recall
rates were found to increase with increasing number of
screening reads per reader over the preceding 12-month
period, but the number of assessment clinics each reader had
attended heavily modified this finding.
13 Hormone replacement therapy, percent mammographic density and the sensitivity of mammography
AM Kavanagh1, JN Cawson2, GB Byrnes3, GG Giles4, G Marr4, DM Gertig3, J Hopper3
1La Trobe University, Melbourne, Australia; 2St Vincents BreastScreen, Melbourne, Australia; 3University of Melbourne, Australia;
4Cancer Council of Victoria, Melbourne, Australia
Breast Cancer Res 2004, 6(Suppl 1):P13 (DOI 10.1186/bcr832)
We examined the extent to which the lower mammographic
sensitivity found in hormone replacement therapy (HRT) users
could be explained by any association of HRT use with higher
density and more difficult to detect cancers (e.g. lobular
cancers). Eligible women included women aged 55 years and
older who attended BreastScreen Victoria for first-round
screening mammography in 1994 and 1995 (1086 breast
cancers) and for subsequent-round screening (471 breast
cancers) in 1995 and 1996. Percent density was measured on
a continuous scale, blinded, using a reliable, computer-assisted
method.
True positive cancers were invasive breast cancers diagnosed
at screening and false negative cancers were cancer diagnosed
within 24 months of a negative screening examination. After
adjusting for age, symptom status, family history, past history of
mammography (at first round) and time since screen (at
subsequent round), HRT users had higher risk of having a false
negative (first round: odds ratio [OR], 1.99; 95% confidence
interval [CI], 1.4–2.9 and subsequent round: OR, 2.29; 95% CI,
1.4–3.8). This effect was attentuated by adjusting for
mammographic density (first round: OR, 1.54; 95% CI, 1.0–2.3
and subsequent round: OR, 1.97; 95% CI, 1.2–3.3), indicating
the density only partly explains the effect of HRT on sensitivity.
14 Size distribution of screen-detected and interval cancers according to breast density suggests
reduced screening benefit for women with higher density breasts
C Nickson1, AM Kavanagh1, GB Byrnes2
1La Trobe University, Melbourne, Australia; 2University of Melbourne, Australia
Breast Cancer Res 2004, 6(Suppl 1):P14 (DOI 10.1186/bcr833)
Previous research has consistently demonstrated lower
mammographic sensitivity for women with denser breasts,
arguably due to masking of tumours in dense breasts. Masking
would be observable as a shift in the size distribution of
Available online  http://breast-cancer-research.com/supplements/6/S1S6
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tumours towards large cancers in dense breasts at screening,
with smaller cancers missed in those breasts appearing later.
We compared tumour size by density and detection point (first
and second round screen-detected and interval cancers) using
quantiles of continuous percentage density and histological
tumour size for 2430 invasive cancers (screen-detected and
interval) detected in Victoria, Australia.
Tumour size increased with density quantile for incident
screen-detected cancers (e.g. median size was 12 mm for
densities less than 4.5% and 15 mm for densities over 26.2%).
The relationship between size and density was more complex
at other detection points. Histograms of size quintiles revealed
patterns consistent with masking. For example, interval tumours
following incident screening showed more cancers in the
smallest size quintile (less than 8 mm) in high-density breasts
(15.4%) than low-density breasts (8.7%), and at second-round
screening low-density breasts revealed more small tumours
(28.3%) than high-density breasts (18.5%).
Australian breast screening missed smaller cancers in women
with high-density breasts, reducing their benefit from the
current breast-screening programme.
15 Using magnetic resonance to diagnose breast cancer and predict therapeutic response
MT Nelson
University of Minnesota, Minneapolis, USA
Breast Cancer Res 2004, 6(Suppl 1):P15 (DOI 10.1186/bcr834)
Introduction: Neoplastic tissue contains elevated levels of
choline-containing metabolites (tCho) [1,2]. The purpose of
this study is to determine whether magnetic resonance
spectroscopy (MRS) with magnetic resonance imaging (MRI)
can be a noninvasive technique for determining whether a
breast abnormality is benign or malignant and to monitor
response to neoadjuvant chemotherapy (CT).
Materials and methods: Women scheduled for a breast
biopsy or scheduled to CT were recruited for our study. All
studies were done with a 4 T MRI/MRS scanner. A baseline
scan was done prior to the start of CT and 24 hours after CT.
Suspicious lesions were identified and measured with a fat-
suppressed high-resolution 3D FLASH image (Gd-TPA,
0.1 mmol/kg). Concentrations of tCho were quantified [3].
Each scan was interpreted by evaluation of lesion size,
architecture, signal intensity, and tCho.
Results: Twenty-six out of 69 patients had infiltrative ductal
carcinoma, 10/69 patients had infiltrative lobular carcinoma,
3/69 patients had ductal carcinoma in situ, 1/69 patients had
lobular carcinoma in situ, and 29/69 patients were found to
have benign breast lesions. Eight patients have been through
CT. Tumor response was seen in six patients. MRS could
detect decreased [tCho] within 24 hours after CT. In the six
patients with decreased [tCho] at 24 hours, 100% showed
diminished tumor size measured by MRI after 9 weeks of CT.
However, the two patients with sustained or elevated [tCho] at
24 hours failed to have response to CT.
Conclusion: Based on these results, we expect that the
addition of MRS to MRI will provide a noninvasive technique for
determining whether a breast abnormality is benign or
malignant. Furthermore, the [tCho] measured at 24 hours
appears to predict response to CT.
References
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16 Scintimammographic findings with 99mTc-(V)DMSA and 99mTc-MIBI in usual-type ductal epithelial
hyperplasia (HUT) and apocrine metaplasia (AM) of the breast, in relation with the cell
proliferation index (Ki-67) and the presence of estrogen receptors (ERs)
V Papantoniou1, J Koutsikos1, M Bembi2, M Sotiropoulou3, S Tsiouris1, E Mainta1, V Valotasiou1, D Lazaris4, CH Zerva1
1Nuclear Medicine Department, Alexandra University Hospital, Athens, Greece; 2Obstetrics & Gynaecology Department, IASO
Hospital, Athens, Greece; 3Pathology Department, Alexandra University Hospital, Athens, Greece; 4Obstetrics & Gynaecology
Department, Alexandra University Hospital, Athens, Greece
Breast Cancer Res 2004, 6(Suppl 1):P16 (DOI 10.1186/bcr835)
Aim: The aim of this study was to assess retrospectively the
ability of 99mTc-(V)DMSA and 99mTc-MIBI to recognize benign
breast lesions such as HUT and AM, with elevated proliferative
activity at different ER status, which have different probabilities
to progress into invasive tumors.
Patients and methods: Twenty-one patients with histologically
confirmed HUT and/or AM were submitted preoperatively to
(V)DMSA and/or MIBI scintimammography, 10 min and 60 min
after administration of 925–1100 MBq each radiotracer.
Immunohistochemical staining was performed using the
avidin–biotin method to determine Ki-67 and ER positivity.
Lesion to background ratios (L/B) were calculated and
compared (t test) with Ki-67 and ER values in HUT and AM
with both tracers (Ki-67 > 3% and ER > 15% were considered
positive).S7
Results: Histology demonstrated HUT in 11 patients and AM
in 10 patients. Mean L/B ratios for (V)DMSA and MIBI in HUT
and AM were 1.71 ± 0.44 (range 1.0–2.6), 1.2 ± 0.23 (range
1.0–1.6), 1.1 ± 0.06 (range 1.0–1.2) and 1.15 ± 0.05 (range
1.05–1.2), respectively. Ki-67 for HUT ranged from 1 to 20%
(mean ± standard deviation [SD], 6.25 ± 5.7) and ER from 0 to
90% (mean ± SD, 43.8 ± 5.7). Ki-67 for AM ranged from 1 to
15% (mean ± SD, 4.83 ± 4.7). In patients with HUT and Ki-67
<3% the mean L/B (V)DMSA ratio was 1.13 ± 0.10, while in
those with HUT and Ki-67 >3% it was 1.89 ± 0.35
(P = 0.0012). In patients with HUT and ER <15% the mean
(V)DMSA L/B ratio was 1.66 ± 0.47, while in ER >15% it was
1.73 ± 0.43 (not statistically different). L/B MIBI ratios were
not significantly different in the groups with higher or lower
Ki-67 and ER values in patients with HUT (1.48 ± 0.45 for
Ki-67 <3% and 1.25 ± 0.15 for Ki-67 >3%). AM did not show
any statistical difference between L/B (V)DMSA and MIBI in
the groups with higher and lower Ki-67 and ER expression.
Conclusion: (V)DMSA uptake in HUT seems to be related to
Ki-67 activity and could be a useful indicator of the probability
of these lesions to progress to atypical hyperplasia, ductal
carcinoma in situ or invasive tumors.
17 The use of bilateral whole breast ultrasound to identify multifocal disease in newly diagnosed
breast cancer
LS Wilkinson, R Given-Wilson, T Hall, H Potts, AK Sharma, E Smith
St George’s Hospital, London, UK
Breast Cancer Res 2004, 6(Suppl 1):P17 (DOI 10.1186/bcr836)
The aim of this study was to evaluate the contribution of
bilateral breast ultrasound in the management of women with
newly diagnosed primary breast cancer.
One hundred and two women presenting with breast cancer
over a 6-month period underwent bilateral breast ultrasound.
Data were collected on pathology, size, invasive status, multi-
focality and surgical outcome. These patients were compared
with 104 patients presenting over a 6-month period, 1 year
previously, who had undergone targeted breast ultrasound.
Thirty-five (34%) of the study patients had multifocal/
multicentric disease diagnosed compared with 18 (15%) of the
control patients. The multiple cancers in the study group were
more likely to be diagnosed by ultrasound, and were more likely
to be multicentric than in the control population. Two
contralateral cancers were identified by ultrasound alone in the
study population. The diagnosis of multifocality changed the
proposed management at surgical review in 8% (95%
confidence interval: 4–14%).
18 Can high-frequency ultrasound predict metastatic lymph nodes in patients with invasive breast
cancer?
GR Clough1, J Truscott2, LIG Haigh1
1St James’s University Hospital, Leeds, UK; 2 University of Leeds, UK
Breast Cancer Res 2004, 6(Suppl 1):P18 (DOI 10.1186/bcr837)
Aim: To determine whether high-frequency ultrasound can
predict the presence of metastatic axillary lymph nodes, with a
high specificity and positive predictive value, in patients with
invasive breast cancer. The clinical aim is to identify patients
with axillary disease requiring surgery who would not normally,
on clinical grounds, have an axillary dissection, so potentially
improving outcome and survival rates.
Materials and methods: The ipsilateral and contralateral
axillae of 42 consecutive patients with invasive breast cancer
were scanned prior to treatment using a B-mode frequency of
13 MHz and a Power Doppler frequency of 7 MHz. The
presence or absence of an echogenic centre for each lymph
node detected was recorded, and measurements were also
taken to determine the L/S ratio and the widest and narrowest
part of the cortex. Power Doppler was also used to determine
vascularity. The contralateral axilla was used as a control for
each patient.
Results: In this study of patients with invasive breast cancer,
ipsilateral lymph nodes with a cortical bulge ≥ 3 mm and/or at
least two lymph nodes with absent echogenic centres
indicated the presence of metastatic axillary lymph nodes (10
patients). The sensitivity and specificity were 52.6% and
100%, respectively, positive and negative predictive values
were 100% and 71.9%, respectively, the P value was 0.001
and the Kappa score was 0.55.
Conclusion: This would indicate that high-frequency
ultrasound can be used to accurately predict metastatic lymph
nodes in a proportion of patients with invasive breast cancer,
which may alter patient management.
Available online  http://breast-cancer-research.com/supplements/6/S1S8
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19 Trends and predictors of size and grade for ductal carcinoma in situ (DCIS) in BreastScreen
Victoria
B Erbas1, P Chang1, AM Kavanagh2, DM Gertig1
1University of Melbourne, Australia; 2La Trobe University, Melbourne, Australia
Breast Cancer Res 2004, 6(Suppl 1):P19 (DOI 10.1186/bcr838)
Previous studies have examined predictors, such as hormone
replacement therapy (HRT) use, of size and grade of invasive
breast cancer, but little is known about factors that influence
prognostic features of DCIS. We evaluated factors associated
with size and grade of DCIS in a large screening programme,
BreastScreen Victoria.
A total of 1127 women were diagnosed with DCIS and 5301
with invasive breast cancer in BreastScreen Victoria between
1993 and 2000. We used multiple linear regression to evaluate
predictors of size and multinomial logistic regression to
evaluate predictors of grade.
The ratio of DCIS to invasive tumours decreased with age but
did not differ by time since the last screen. Older age (over
70 years) was associated with smaller DCIS size and better
differentiated tumours (P = 0.05) compared with women aged
50–69 years. A longer screening interval was associated with
larger DCIS tumours (P = 0.01) but was not associated with
grade of DCIS. There was a borderline significant association
between current HRT use and decreased risk of high-grade
DCIS lesions (P  = 0.07) in univariate analyses, but this
disappeared after adjustment for size and histology.
There are important differences between predictors of DCIS
and invasive cancer. In contrast to invasive cancer, HRT is not
associated with size or grade of DCIS.
20 Screen-detected lobular carcinoma in situ (LCIS) of the breast: 166 cases within the National
Health Service Breast Screening Programme (NHSBSP)
RKF Hogben1, MW Kissin1, C de Vries2, P Jackson1, C Kissin1
1Royal Surrey County Hospital, Guildford, UK; 2University of Surrey, Guildford, UK
Breast Cancer Res 2004, 6(Suppl 1):P20 (DOI 10.1186/bcr839)
Background: LCIS is classically an incidental finding on breast
biopsy with no positive mammographic features. However,
screening has identified a small number of cases of pure LCIS.
Aim:  To review cases of screen-detected LCIS within the
NHSBSP programme since its inception.
Methods: Cases of pure LCIS were identified via Quality
Assurance offices and screening centres. Mammograms and
pathology were reviewed and recurrence/survival data
obtained. New immunohistochemistry was performed on the
available pathology blocks.
Results: One hundred and sixty-six cases of screen-detected
LCIS were identified in 20 centres since 1988. One hundred
and seven (64%) presented with calcifications on
mammography, 25 (15%) with a mass lesion and 34 (21%)
with distortion or asymmetry. The preoperative diagnosis rate
with core biopsy was 28/84 = 33%.
Of 106 patients in which follow-up was available to date, six
went on to get an invasive cancer at a median time of 60
months; four of these were unilateral.
Conclusions: Screen-detected LCIS is a rare but important
lesion. Preoperative diagnosis is difficult. Invasive recurrence is
1% per year of follow-up.
21 Radiological and histological features of mammography screen-detected lesions having
undergone benign surgical excision
DD Manuel, S Bose, RK Wasan, G Ralleigh, DR Evans, MJ Michell
King’s College Hospital NHS Trust, London, UK
Breast Cancer Res 2004, 6(Suppl 1):P21 (DOI 10.1186/bcr840)
Aim: The development of modern image breast-guided biopsy
techniques including core biopsy and vacuum-assisted core
biopsy has improved the nonoperative diagnosis for most
screening mammography-detected lesions, leading to a
decrease in benign surgery. The aim is to describe the
radiology and histology of benign screen-detected lesions
requiring surgical excision in our practice.
Method: From April 1998 to March 2003, 155,621 women
were screened in the South East London Breast Screening
Programme, 8836 women were assessed (5.7%), and 182
benign lesions were surgically removed (0.1% of women
screened). Radiological and histological features were
recorded on a database.S9
Results: The primary histological diagnosis was: fibrocystic
change (FCC) (26%), radial scar/complex sclerosing lesion
(CSL) (24%), fibroadenoma (FA) (14%), papilloma (11%),
atypical ductal hyperplasia (ADH) (7%), and miscellaneous
other (15%).
The mammography features of benign lesions excised were
well-defined mass (38%), microcalcifications (28%), stellate
distortion (28%), asymmetry density (3%), and 4% other signs.
The commonest histology for each mammography sign was:
microcalcifications, FCC (40%), papilloma (11%), FA (9%), ADH
(8%), CSL (6%); well-defined mass, FA (28%), FCC (25%),
papilloma (18%), CSL (10%); and architectural distortion,
CSL/radial scar (78%), only 16% in FCC with 6% in FA.
Conclusion: This study confirms that modern breast biopsy
techniques decrease the need for surgery for benign lesions,
particularly microcalcifications due to FCC. A further decrease
in the need for surgical biopsy may be anticipated as
techniques improve and data showing the effectiveness of
nonoperative diagnosis of such as CSL/radial scar and
papilloma become available.
22 How spiculation affects the likelihood of malignancy in screen-detected masses: a review of 974
masses excised in the first 8 years of the East Sussex, Brighton & Hove Breast Screening Service
S Horn1, C Zammit1, A Yelland1, G Rubin2
1Breast Surgical Unit, Royal Sussex County Hospital, Brighton, UK; 2Breast Assessment Centre, Royal Sussex County Hospital,
Brighton, UK
Breast Cancer Res 2004, 6(Suppl 1):P22 (DOI 10.1186/bcr841)
Background: The presence of spiculation arising from a mass
detected at mammography makes malignancy a probable
diagnosis. This is confirmed by this review of the first 8 years of
screening in East Sussex where only 3.6% of masses with
spiculation were benign at excision (24 out of 668), compared
with 33.3% of masses without spiculation (102 out of 306).
Methods and results: The mammographic appearances of
screen-detected lesions were prospectively recorded at the
time of assessment. Features recorded for masses were the
presence or absence of spiculation and microcalcification.
Those undergoing excision were entered onto the former South
East Thames Screening database. The mammographic
features and type of lesion are presented in Table 1.
Most of these lesions were excised during the era when we
performed fine needle aspiration rather than the core biopsies
we use today and it was our policy to excise all mass lesions
showing spiculation. The very small number of benign surgical
biopsies in this group shows that the policy was justified.
Table 1
Number of benign  Number of in situ Number of 
Mammographic feature lesions (%) cancers (%) invasive cancers (%) Total
Mass with spiculation and microcalcalcification 7 (4.3) 4 (2.4) 153 (93.3) 164
Mass with spiculation and no microcalcification 17 (3.4) 4 (0.8) 483 (95.8) 504
Total with spiculation 24 (3.6) 8 (1.2) 636 (95.2) 668
Mass without spiculation but with microcalcification 27 (30) 11 (12.2) 52 (57.8) 90
Mass without spiculation or microcalcification 75 (34.7) 12 (5.6) 129 (59.7) 216
Total without spiculation 102 (33.3) 23 (7.5) 181 (59.2) 306
23 Ductal carcinoma in situ (DCIS): are we overdetecting it?
A Evans
Breast Institute, City Hospital, Nottingham, UK
Breast Cancer Res 2004, 6(Suppl 1):P23 (DOI 10.1186/bcr842)
DCIS constitutes approximately one-quarter of screen-
detected cancer. The proportion of screen-detected cancer
that is DCIS decreases with the age of the screening
population. Whether detecting DCIS at mammographic
screening is of benefit depends on the natural history of the
DCIS detected at screening and whether DCIS detection
enables the detection of invasive foci already present within
DCIS lesions.
The natural history of DCIS varies according to the grade of the
DCIS detected. The natural history of low grade DCIS is that
approximately 60% of lesions will become invasive at 40 years
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follow-up. The natural history of high grade DCIS derived from
local recurrence rates within high grade DCIS lesions, which
have been inadequately resected and not given radiotherapy,
suggests an invasive risk of at least 50% at 7 years follow-up.
Given the average life expectancy of women with screen-
detected DCIS is 25 years, this suggests high grade DCIS is
an obligate precursor of invasive disease. There is a strong
correlation between the grading of invasive cancer and the
grade of DCIS from which it arose. This suggests that
approximately 50% of low grade DCIS detected at screening
will represent overdiagnosis while overdiagnosis of high grade
DCIS would be rare. The natural history of intermediate grade
DCIS is as yet unknown. Only 15% of screen-detected DCIS is
low grade, suggesting that overdiagnosis is uncommon.
Approximately 60% of screen-detected DCIS is high grade and
in the vast majority of these patients adequate treatment will be
preventing the occurrence of high grade invasive breast
cancer. Approximately one-third of malignant calcification
clusters detected at screening mammography already has an
invasive focus. These invasive foci are usually small and high
grade. Data gathered from all the units in the National Health
Service Breast Screening Programme indicate a strong
correlation between the detection of DCIS and the detection of
small invasive cancers. These data indicate that for every two
cases of DCIS detected, one case of a small invasive cancer is
also detected. These data indicate that DCIS detection within a
mammographic screening programme prevents the occurrence
of high grade invasive cancer and aides the detection of small
invasive cancers at a size where treatment can be successful.
Overdiagnosis will occur in approximately one-half of the cases
of low grade DCIS detected. This represents approximately 2%
of screen-detected lesions. If one assumes the natural history of
intermediate grade DCIS is intermediate between low and high
grade disease then overdiagnosis of DCIS within a screening
programme may represent 3% of screen-detected lesions.
24 Ductal carcinoma in situ (DCIS): are we overtreating it?
JM Dixon
Edinburgh Breast Unit, Western General Hospital, Edinburgh, UK
Breast Cancer Res 2004, 6(Suppl 1):P24 (DOI 10.1186/bcr843)
DCIS continues to increase in incidence as the number of
women invited to population breast screening programmes
increases. This means that more women are treated every year
for DCIS. More women diagnosed with DCIS currently receive
some form of treatment and the issue is whether this treatment
is necessary and appropriate.
There are few data on the natural history of untreated DCIS.
Studies from Nashville by Page [1] show 28% of patients with
low grade DCIS develop invasive disease by 6 years and 40%
have developed invasive disease by 30 years. Data from Van
Nuys [2] suggest that the rate of progression in high grade
DCIS is much higher, with 60% of women with incompletely
excised high grade disease developing progression or invasive
cancer by 5 years.
The results of studies on treatment of DCIS can be
summarised as follows:
• Excision alone is associated with a high rate of local
recurrence in approximately 3.8% per year, of which 1.6%
per year is invasive disease.
• Radiotherapy reduces the recurrence rate in the
progression to invasive cancer by between 50 and 60%.
• Recurrence rates are lower when radiotherapy is given to
patients whose lesion is completely excised with clear
margins. The evidence that wider margins is associated
with better local control rates does not stand up to scrutiny.
Surgeons in the UK are divided as to what they consider to
be an adequate clear margin width.
• Tamoxifen reduces recurrence rates in oestrogen receptor-
positive DCIS but not oestrogen receptor-negative DCIS.
• No patients with localised DCIS should have axillary
surgery.
As the numbers of patients with DCIS increases, so the
number of women being treated by breast-conserving surgery
and mastectomy increases. The challenge is to limit the surgery
so as to reduce morbidity and select those patients who will
have most to gain from radiotherapy and tamoxifen.
References
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25 The Sloane Project
H Bishop
Royal Bolton Hospital, Bolton, UK
Breast Cancer Res 2004, 6(Suppl 1):P25 (DOI 10.1186/bcr844)
Ductal carcinoma in situ (DCIS) is a disease discovered by
screening. Fifteen years after the introduction of the UK Breast
Screening Programme we have belatedly recognized that it is a
fascinating disease about which we, in reality, know very little.
Early trials in DCIS have recruited small numbers and have not
delivered definitive results. Nevertheless, thanks to
improvements in radiology the detection of new DCIS cases
has gone up. In 1996/97, 1468 cases of DCIS wereS11
detected; by 2002/03 this had increased to 2416, an
increase of 65%.
These numbers represent a significant and as yet untapped
resource of data about this group of patients. The aim of the
Sloane Project is to audit all screen-detected noninvasive
disease.
Over 5 years it should be possible to collect data on over
10,000 patients with noninvasive disease. Data are collected
contemporaneously on radiology, pathology and treatment. We
aim to audit local recurrence and survival.
With large numbers it should be possible to inform clinicians
and thus their patients of the likely risks and benefits of
individual treatments.
The Sloane Project does not exclude any screen-detected
patient, it actively encourages trial recruitment but its potential
is to be the largest audit of noninvasive screen-detected
cancer in the world.
In recognition of his seminal contributions to DCIS the project
is named after John Sloane. (For details on contributing
patients, please contact Karen Clements, Sloane Project
Officer. Tel: +44 121 414 7713.)
26 Workforce issues
A Paterson
The Society and College of Radiographers, London, UK
Breast Cancer Res 2004, 6(Suppl 1):P26 (DOI 10.1186/bcr845)
The prevention, diagnosis and treatment of breast disease
requires an integrated approach to healthcare, and a workforce
that is able to function interprofessionally and across the
spectrum of healthcare from public health and preventative
care to care of patients in the terminal stages of their disease. It
is important to remember this when addressing workforce
issues, especially when focusing on one section of the
workforce community, the radiography workforce.
Changes to the National Breast Screening Programme have
necessitated an increase in the size of the workforce to carry out
the screening mammograms, and an increase in workforce
elsewhere to deal with the subsequent additional demand for
further assessment and treatment. This has coincided with a
severe shortage of radiographers and radiologists, two key
groups in the workforce. This has led to a re-examination of roles
and responsibilities of staff and the tentative introduction of the
career progression framework for the radiography workforce.
This presentation outlines the career progression framework
with particular reference to the National Breast Screening
Programme. It identifies key challenges that this has brought;
for example, education and training; role boundary blurring; and
professional patch protectionism. It will also offer some
potential solutions, which, together, should help meet the
needs of clients and patients.
27 Two-view mammography: the Welsh experience and overview
K Gower Thomas
Breast Test Wales Cardiff, UK
Breast Cancer Res 2004, 6(Suppl 1):P27 (DOI 10.1186/bcr846)
In Wales, population breast screening using mammography,
within the National Health Service Breast Screening
Programme (NHSBSP), commenced in February 1989. It was
gradually rolled out across the Principality over the next 3 years
by Breast Test Wales with the prevalent screening round
completing in 1995.
From its inception, two-view mammography was the standard
for all prevalent round screens in Wales, unlike many other
screening programmes that relied on a single view. This
resulted in higher than expected cancer detection rates as
compared with the Swedish Two County trial and other
NHSBSP results. In Wales 9.2 breast cancers per 1000
women screened were found compared with an average of 6.3
per 1000 in the rest of the UK in the prevalent round.
For incident round screens, it was decided that single-view
mammography was appropriate. The results were less
impressive, with cancer detection dropping to standardised
detection ratio values of less than one. There may be several
reasons for this anomaly, not least of which is the possibility
that more subtle cancers, including those only visible on the
cranio-caudal view, had been identified at the prevalent screen
and were thus not present to be picked up at subsequent
incident rounds.
In 2000, when the National Assembly for Wales made monies
available to extend screening up to the age of 70 years, it was
decided that, firstly, the programme should revert to two-view
screening, but this time for all rounds. The results of these first
two-view incident round figures will be presented. There has
been an increase in cancer detection of around 39%, similar to
that predicted by Blanks and Moss in their studies. The first
18 months of two-view incident round screening increased the
cancer detection rate in these women from 5.38 to 7.5 per
1000 screened. This included an increase in the small cancers
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detected from 2.30 to 3.30 per 1000. The recall to assessment
figures also rose, surprisingly from 3.8% to 4.5%, although the
rise has not been sustained more recently. In some areas the
first incident two-view round has been completed; data on this
will be presented.
It is, however, unlikely that this increase in cancer detection will
persist in subsequent incident rounds and a steady state will
be reached, but at a higher level of cancer detection than with
single-view incident screening.
It is hoped that, in contrast, the interval cancer rate will drop
accordingly. Early data on interval cancers will also be
presented.
28 Overview of recent changes to the National Health Service Breast Screening Programme
(NHSBSP): impact on the service
J Patnick
NHS Cancer Screening Programmes, Sheffield, UK
Breast Cancer Res 2004, 6(Suppl 1):P28 (DOI 10.1186/bcr847)
The NHS Cancer Plan of October 2000 announced two major
changes to the NHSBSP. These were the introduction of two
views to all screens and the expansion of the programme to
include women aged 65–70. These changes together
amounted to a 40% increase in workload and were to be
introduced by the end of 2003 and 2004, respectively.
In order to cope with this expansion, new ways of working were
developed. Many services already have assistant practitioners
taking mammograms and radiographers undertaking elements
of advanced practice, some of the latter are operating fully as
advanced practitioners. A new computer system has been
introduced and there has been a major re-equipping of the
service.
All but a handful of screening programmes are now taking two
views at each screen, and four out of 10 have expanded to
include 70 year olds. With the exception of only a few, the rest
should all be working to the new target age range by the end of
this year.
Round length is now the most vulnerable area of the screening
programme. Services are sometimes struggling to cope with
delivering a high-quality expanded programme and maintaining
3-yearly screening.
29 Interim results from the Age Trial
S Moss, M Waller, T Anderson, H Cuckle
Reproductive Epidemiology, University of Leeds, UK
Breast Cancer Res 2004, 6(Suppl 1):P29 (DOI 10.1186/bcr848)
Since 1991, 160,884 women were randomised in the ratio 1:2
to intervention (annual mammography from age 40 to 41) and
control arms. All breast cancers diagnosed in both arms were
identified, and subjected to detailed histology review. Predicted
deaths from breast cancer up to 10 years from entry were
calculated using three different prognostic indices, based on
1287 cases diagnosed before 2000.
There is currently an 8% excess of invasive breast cancers in
the intervention arm, but nonsignificant decreases in the rates
of cancers ≥20 mm and node-positive cancers. The ratio of
predicted deaths in the intervention and control arms, adjusted
for the excess diagnosis in the intervention arm, ranges from
0.89 to 0.90, and is borderline significant.
This trial may result in a smaller breast cancer mortality reduction
than other trials of women aged under 50, due to inclusion of all
women from age 40 with possible lower sensitivity at younger
ages. However, the present analysis, based on surrogate
outcome measures, relies on several assumptions to overcome
potential biases. Firm conclusions must await the analysis of
observed mortality from breast cancer.
30 Radiological results of the Age Trial
A Evans
Breast Institute, City Hospital, Nottingham, UK
Breast Cancer Res 2004, 6(Suppl 1):P30 (DOI 10.1186/bcr849)
Almost 500 cancers occurring within the study arm of the Age
Trial have had their radiological features reviewed. The
commonest radiological features of screen-detected cancers in
this age group are granular microcalcification (28%), spiculate
mass (22%), poorly defined mass (20%) and comedo
calcification and parenchymal distortion both at 18%. Of the
254 cancers detected at screening that had a previous screen,
52% showed some mammographic feature on the previous
screen. The most frequent abnormality in such cases was
granular microcalcification 44%, parenchymal deformity 17%S13
and poorly defined mass 17%. Of the 138 interval cancers
reviewed, 30% had abnormalities visible on previous screens.
The commonest features present on previous screens were
microcalcification, asymmetric density and ill-defined mass.
The radiological features of cancers arising in younger women
who are being screened are different to those occurring in
older women. Spiculate masses are less common and
microcalcification is more common in this age group.
Microcalcification is also a common feature of screen-detected
cancers visible on previous screens.
False negative interval cancers show a more varied distribution
of radiological features, with asymmetric density, parenchymal
deformity and microcalcification all being important features.
31 Pathology results from the UK Age Trial
IO Ellis1, TJ Anderson2, M Waller5, L Bobrow3, A Hanby4, S Moss5
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Breast Cancer Res 2004, 6(Suppl 1):P31 (DOI 10.1186/bcr850)
The UK Age Trial was initiated in 1991 to address the question
of whether annual mammography from age 40 years reduces
mortality from breast cancer and by what percentage. At
present, only surrogate end points generated by pathology
review of cancers can be used for a preliminary estimate of
mortality/survival benefit for the study arm. All cases of breast
cancer in the appropriate age range were systematically
identified and relevant material retrieved for centralised, blinded
review by a panel of three pathologists following classification
principles outlined in the UK Guidelines. The total number of
cancers identified in the Trial population up to 31 December
1999 was 1288.
There was a high proportion of special types in incidence and
interval cancers but the explanation in each set differs; for
incidence cases the preponderance is for tubular cancers,
while for interval cases it is lobular cancers. For grade,
incidence screens yielded the highest proportion of grade I and
a low grade III, whereas interval cancers showed the converse,
with low grade I and high grade III proportions. For node status,
the highest negative proportion was found for incidence
screens and the lowest was seen in ‘never attended’ cases.
These features provide clear confirmation of the length bias
influence anticipated for the screened subpopulations, but they
are not fully informative for screening effects or for
understanding cancer natural history.
32 Chemoprevention for breast cancer: current status
P Boyle
Director International Agency for Research on Cancer, Lyon, France
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33 Digital imaging: Digital Mammography Imaging Screening Trial Project
M Rebner
William Beaumont Hospital, Royal Oak, Michigan, USA
Breast Cancer Res 2004, 6(Suppl 1):P33 (DOI 10.1186/bcr852)
The Digital Mammography Imaging Screening Trial was formed
to determine whether digital mammography could detect
breast cancer as well as, or better than, film mammography.
Since 2001, 35 facilities helped enrol the 49,528 patients in
the US and Canada. Each study participant had a digital
mammogram and a film examination. A follow-up mammogram
was obtained 1 year after the initial study to determine breast
health status. The study completed its accrual in November
2003. One-year follow up mammograms are currently being
performed. Over the next 18 months 84 radiologists will
interpret soft copy, digital hard copy and film images.
Parameters to be analyzed include: diagnostic accuracy of
digital monitor images, effect of breast cancer prevalence on
the radiologist’s interpretation, effect of breast density on
diagnostic accuracy of digital and film mammography, and the
diagnostic accuracy of different digital and film units.
Each facility was required to meet strict quality control
standards for both digital and film screen mammography. In
addition, each facility was inspected to ensure proper record
keeping and documentation. The results from this study should
prove beneficial to breast cancer diagnosis and treatment.
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34 Digital imaging: technical developments and UK perspective
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A remarkable variety of designs for full-field digital mammography
have been developed. Computed radiography systems, using
laser-stimulated photo-stimulable phosphor technology, which
are widely used for general radiography, are increasingly also
used for mammography. Computed radiography has received a
new lease of life with the introduction of dedicated dual reading
technology at 50 µm pixel size. Other designs have integrated
digital detector systems where the detector and read-out
mechanism are built into the breast platform. The quality of
display monitors is regarded as crucial and dual cathode ray tube
displays with 2000 × 2500 resolution are becoming standard,
but it is likely that high-resolution liquid crystal displays will
supplant these. Although most systems demonstrate an image
quality that is superior to existing film screens, some are inferior.
New standards are being introduced for image quality to verify
that new digital systems have a performance that is at least as
good as current systems. While digital systems may be readily
introduced into a symptomatic role, their use in screening is more
problematic because of the high throughput required for both
acquisition and display. A number of informal trials of digital
systems in screening and assessment environments are taking
place in the UK.
35 Computer-aided detection (CAD): the case for
S Destounis
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Breast Cancer Res 2004, 6(Suppl 1):P35 (DOI 10.1186/bcr854)
In any discussion regarding the necessity for CAD, the ultimate
goals of a screening programme must be taken into consideration
balanced against the cost of instituting the programme. Double
reading has been shown to increase sensitivity by as much as
15%. However, the cost no matter the method is formidable.
CAD, on the other hand, while initially costly, has been shown
to increase the sensitivity by as much as 23%. This increase in
sensitivity is reason enough to use CAD, but must be evaluated
in the context of effect on positive predictive value and recall
rates. Our clinic first viewed CAD with the same concerns. Our
studies to date indicate no statistically significant change in
positive predictive value or recall rate. Despite an independent
double-blinded double read, CAD increased sensitivity by 7%.
Some studies have shown that increased sensitivity with CAD
is due to ductal carcinoma in situ detection, but this was not
shown in our prospective study. In our group of cancers, 87%
were stage 0 or stage 1 and 77% were minimal cancers
(<10 mm invasive or any size ductal carcinoma in situ).
However, the cancers that the double read missed and CAD
prompted were all invasive with only 57% minimal disease.
36 Computer-aided detection (CAD): the case against
R Given-Wilson
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Breast Cancer Res 2004, 6(Suppl 1):P36 (DOI 10.1186/bcr855)
CAD places prompts to alert readers to potential lesions.
Readers can decide whether to initiate further assessment.
Currently, commercially available CAD systems are highly
sensitive and will prompt 94% of detected cancers (98.4%
microcalcifications, 89% masses). Prompt rates on missed
cancers are lower but the majority are prompted (52–77%).
A number of published evaluations of CAD benefit
extrapolate from these rates. They assume that readers will
respond appropriately to every correct prompt and initiate
recall. Studies in vitro and in real life show variable reader
response, with increases in cancer detection ranging from
0% to 22%.
There is lower specificity with one to two false prompts per case.
In UK screening, readers will dismiss over 1000 false prompts
for every true prompt, which should change their outcome
decision. This makes discrimination difficult. When investigating
missed cancers we have found readers are more likely to dismiss
than act on true prompts. In addition, CAD increases reading
time and can increase recall rate, thus increasing cost. This is
offset in the US by higher reimbursement for CAD reading but
would be cost increasing in the UK.
CAD technology is improving and may shortly be beneficial but
at present its role in the UK is unproven.S15
37 Sonographic assessment of extent and aggressiveness of malignant breast disease
T Stavros
University of Colorado, Denver, USA
Breast Cancer Res 2004, 6(Suppl 1):P37 (DOI 10.1186/bcr856)
While contrast enhanced magnetic resonance imaging (MRI) is
generally considered the modality of choice for staging
malignant breast disease and PET/CT is considered the
modality of choice for staging distant spread, ultrasound (US)
can also be used to assess the local extent of malignant breast
disease in many patients. Most patients will undergo breast
sonography prior to breast MRI or PET/CT. Thus, US offers us
our first chance to determine the local extent of disease in
many cases. US is good enough at ‘staging’ that in any patient
with a solid nodule characterized as BIRADS 4 or BIRADS 5
we routinely perform whole breast US and assess the axillary
lymph nodes during the initial sonogram or immediately prior to
performing US-guided biopsy of the index lesion.
US staging involves determining the maximum diameter of the
index lesion, assessing for multifocal and multicentric disease,
and looking for the presence of extensive intraductal
components (EIC). Regional lymph nodes can also be
assessed sonographically at the same time that the suspicious
index solid nodule and ipsilateral breast are evaluated. US-
detected secondary and tertiary lesions can, and should, be
‘mapped out’ with US-guided biopsies.
Accurate US staging leads to the appropriate type of extirpative
surgery, minimizes the number of surgeries necessary to rid the
patient of disease, and can minimize the risk of local recurrence.
In fact, ‘local recurrence’ is almost always residual unresected
disease that was not recognized preoperatively or
intraoperatively by the surgeon. It can also obviate staging MRI
and sentinel node procedures in some cases.
We then place nine individual suspicious findings into three
categories: ‘hard’, ‘soft’, and ‘mixed’ suspicious findings. ‘Hard’
findings suggest the presence of invasion, and include angular
margins, spiculation, and acoustic shadowing. ‘Soft’ findings
suggest the presence of ductal carcinoma in situ (DCIS)
components, and include duct extension, branch pattern,
calcifications, and most cases of microlobulation. It is important
to include soft findings in the sonographic algorithm because
they improve the sensitivity for pure DCIS, but also because
they help us to better assess the true extent of lesions that
contain both invasive and intraductal components. Most invasive
ductal carcinomas contain DCIS components, which frequently
lie in the periphery and contribute to the surface characteristics
and shape of the lesion. ‘Mixed’ findings are not specific and
can be seen with either invasive or DCIS components of the
lesion, and include taller-than-wide (antiparallel) shape,
hypoechogenicity, and a minority of microlobulations.
The most basic prognostic feature of a malignant lesion is its
maximum diameter. There are two different maximum
diameters—the prognostic diameter used in determining the
TNM stage and the surgical diameter necessary to completely
remove the lesion. The prognostic diameter is the maximum
diameter of the invasive component of the tumor, and is
represented sonographically by the largest part of the lesion
than manifests hard sonographic findings. The resection
diameter includes both invasive and DCIS components of the
tumor and is represented sonographically by the greatest
length of combined hard and soft findings in the lesion.
Multifocal invasive carcinoma usually represents separate foci
of invasion in a single malignant lesion that are connected by
DCIS components of the lesion. By scanning parallel to the
long axis of the mammary ducts in the region of a suspicious
breast nodule, we are frequently able to show ‘bridges’ of
DCIS connecting the foci of invasion.
EIC increase the likelihood of local recurrence in patients who
undergo breast-conserving therapy. Prominent ‘soft’ findings
suggest the presence of EIC.
Certain suspicious sonographic features correlate with the
histologic grade of the lesion or with the nuclear grade of the
DCIS components of invasive ductal carcinomas. The
presence of enhanced through-transmission deep to a
suspicious solid nodule more than doubles risks that the lesion
is high grade. Shadowing favors the lesion being low or
intermediate grade. The thicker the ill-defined echogenic halo
relative to the size of the hypoechoic central nidus, the more
likely the lesion is to be low grade. Circumscribed malignant
nodules that are surrounded by a thin echogenic capsule are
more likely to be high-grade invasive ductal carcinomas or
special-type tumors such as colloid or medullary. Large
microlobulations and branch pattern suggest a high-grade
lesion, intermediate-sized microlobulations and branch pattern
suggest an intermediate-grade lesion, and very small
microlobulations suggest the presence of a low-grade lesion.
Once we have completely evaluated the breast to look for
multifocal and multicentric disease and EIC, we proceed to
evaluate the axillary lymph nodes. If abnormal lymph nodes are
found, we perform US-guided biopsy of the lymph node. If the
biopsy is positive for metastatic disease, the sentinel lymph node
procedure becomes unnecessary and the patient proceeds
straight to axillary dissection. If the biopsy is negative for
metastatic disease, the patient undergoes the sentinel node
procedure as originally planned. There is a distinct advantage to
this pattern of sonographic evaluation. The sentinel node
procedure is not perfect. False negative sentinel node procedures
occur in a small percentage of patients. In such cases, the cause
of failure is ‘tumor damming’. Metastases to the sentinel node
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block the normal lymphatic drainage through the sentinel node,
causing it to go through collaterals to a higher node that may still
be histologically negative. Sentinel nodes that are so grossly filled
with tumor that they alter the normal lymphatic drainage pattern
are easily identified as being abnormal by sonography and can
easily be targeted for US-guided biopsy.
38 Phantom experiments for measuring elasticity of breast cancer by the echo technique
Y Hayakawa, R Horii, K Tsuji, H Doi
Toin University of Yokohama, Japan
Breast Cancer Res 2004, 6(Suppl 1):P38 (DOI 10.1186/bcr857)
Breast cancer is more stiff compared with benign lesions. The
aim of the experiment is to measure the elasticity by pressing
the breast with a water bag and measuring the shape change
by the echo technique. The ultrasound frequency was 8 MHz.
Two kinds of phantoms were created. One is made of silicone
rubber 50 mm in thickness and inside is a polymethyl-
methacrylate (PMMA) cylinder of diameter 20 mm. The PMMA
cylinder is mocking the cancer and is placed with the surface at
10 mm and 20 mm depths from each silicone rubber surface.
Another phantom is made of gelatine of 30 weight percent to
water instead of silicone rubber. The phantoms were placed
between two PMMA plates and pressed by a balloon filled
with water, which is connected to a vessel by a rubber tube.
The height of the vessel can be adjusted to change the
pressure of the balloon. The silicone rubber phantom was
too hard to be deformed by water pressure. The gelatine
phantom was deformed around the PMMA cylinder by water
pressure of up to 3.4 kPa. The gelatine surface was
deformed by gravity without water pressure. Apparent
differences of gelatine surface deformation depending on
different water pressure were confirmed from the echogram
thus obtained.
39 The management of X-ray quality control data in mammography applications: an information
technology approach to solving the problem
PA Connolly, N Pearson, P Charnock, BM Moores
Integrated Radiological Services Ltd, Liverpool, UK
Breast Cancer Res 2004, 6(Suppl 1):P39 (DOI 10.1186/bcr858)
Mammographic equipment quality control procedures require
that upwards of 35 items of data are recorded from each of 31
mammographic X-ray units per week, for which the Integrated
Radiological Services provides medical physics support. The
data are garnered from four main quality assurance (QA) areas;
automatic exposure control monitoring, tube output data, image
quality assessment and film processor monitoring (sensitometry).
This adds up to some 1085 items per week or over 56,000
items per year. These data are collected by QA radiographers in
both screening and symptomatic units on paper records, which
are then sent to the Integrated Radiological Services where the
data are input to a central database for storage and analysis.
During a typical year this would require 50 man-days of medical
physics input to be devoted to this task. An information
technology-driven database system has been in use for some
time to facilitate the central storage, analysis and management of
these data. This paper reports on the implementation of a data
interface, using personal digital assistant technology, between
the user (QA radiographer) and the data management system.
This personal digital assistant approach streamlines the data
entry to the management system and the transfer of data to the
central assessment facility.
40 The impact of digital stereotactic devices on examination times
A Burch, K Gower-Thomas
Breast Test Wales, Cardiff, UK
Breast Cancer Res 2004, 6(Suppl 1):P40 (DOI 10.1186/bcr859)
One of the perceived benefits of digital stereotactic devices over
film-based ones is a reduction in examination time. However,
there is a lack of published evidence to demonstrate this. A study
was undertaken to compare the duration of examinations by
recording the timing of events (including start and end times)
during routine use of film-based and digital devices. The median
times were compared using the Mann–Whitney U test.
The median times for film-based systems were 35 min for core
biopsies (n = 48), 26 min for fine needle aspirations (n = 64)
and 22 min for wire localisations (n = 24). The times for digital
systems were 25 min for core biopsies (n = 92), 19 min for fine
needle aspirations (n = 59) and 15 min for wire localisations
(n = 56). Thus digital systems reduced the examination time by
approximately 30%, offering a potential increase in patient
throughput. The total compression time was reduced by 3–7 min;
this may improve patient comfort. The time between applying
compression and inserting the first needle was reduced by
4–6 min; this may improve positional accuracy by lessening the
chance of patient movement. All differences were statistically
significant.
This study demonstrates that digital systems offer a real
reduction in examination time.S17
41 Compression/encryption technology applied to Dicom/digitised mammography
RW Grant, MJ Alsewan, MC Devlin
Victoria Breast Screening Centre, Romford, UK
Breast Cancer Res 2004, 6(Suppl 1):P41 (DOI 10.1186/bcr860)
There is an increasing need for teleradiology services that enable
images to be sent to other centres for further opinion, plus the
collation of research data with images from many different
medical institutions. Mammography has specific and demanding
requirements, and in testing a new Dicom compression and
encryption tool it was apparent that it can cope with very large
files such as a set of four Dicom mammograms. The 256 bit (32
characters) encryption provides appropriate data protection for
transmission of the compressed images, while the original Dicom
images remain unchanged on the host system. Four sets of
Dicom mammograms were compressed and prepared on disc as
a series using the originals in one set, and varying levels of
compression to six other series. These were viewed by various
consultants on a personal computer to determine whether the
image quality is acceptable for diagnosis, and evaluated on a
scale of 1–5. A 34 MB patient set can be compressed to fewer
than 300 kB without losing data. A separate analysis of all pixels
in the image for both original and compressed formats give an
indication of ‘Lossless’ and ‘Lossy’ 1/3 levels. The applications of
this technology will be considered.
42 Image-guided interventional procedures of the breast: the development and delivery of a
postgraduate programme of study from an academic and clinical perspective
ME Fletcher1, JL Horrocks2
1General Infirmary at Leeds, UK; 2University of Leeds, UK
Breast Cancer Res 2004, 6(Suppl 1):P42 (DOI 10.1186/bcr861)
It is acknowledged that advanced practitioners [1] can, if
suitably trained, undertake interventional procedures of the
breast under mammographic/ultrasound control.
While the idea of mammographers/ultrasonographers under-
taking interventional procedures remains controversial, it is
established practice in a small number of centres, through ‘in-
house’ training [2]. However, some concern has been expressed
at the nontransferability of the skills acquired by ‘in-house’
training, and the need for formal academic input of required
underpinning knowledge and accreditation of competencies is
now recognised [3]. This can only be achieved by academics
and clinical specialists working in collaboration [1].
This paper discusses the problems associated with the
development and delivery of such a postgraduate programme
from an academic and clinical perspective.
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43 Breast compression revisited
AE Poulos1, D McLean1, MT Rickard2, R Heard1
1University of Sydney, Australia; 2BreastScreen NSW, Sydney, Australia
Breast Cancer Res 2004, 6(Suppl 1):P43 (DOI 10.1186/bcr862)
Introduction: Breast compression is essential in mammography
to reduce breast thickness. Breast thickness reduction reduces
the radiation dose and increases the image quality. Breast
compression also unfortunately causes discomfort to many
women and may deter them from attending for breast screening
by mammography. It is essential, therefore, that an optimum
amount of compression is applied to minimise breast thickness.
Current protocols suggest that breast compression should be
applied until physical changes to the breast are observed. Two
studies were conducted to investigate the relationship between
applied compression force and breast thickness reduction.
Methods: Study 1 investigated changes in breast thickness
when applied breast compression was reduced, while study 2
compared the compression force and resultant breast
thickness recorded clinically with that recorded under
experimental conditions.
Results: The results suggest that applying compression does
not ensure breast thickness reduction and observing physical
changes does not guarantee that breast thickness has been
minimised.
Discussion: The protocols for the applying compression must be
changed to emphasise the need for minimising breast thickness.
Mammography machine digital displays should be revised.
Conclusion: The goal of mammographic practice must be to
minimise breast thickness while acknowledging the potential
for discomfort to be experienced.
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44 Cysts: are they always benign?
S Chandrasekharan, R Whitney
Colchester and Chelmsford Breast Unit, Colchester, UK
Breast Cancer Res 2004, 6(Suppl 1):P44 (DOI 10.1186/bcr863)
Introduction: We present here four cases of atypical cysts.
Cysts are one of the commonest benign lumps seen in a breast
clinic. Rarely cysts can show some atypical features, on clinical
assessment or on ultrasound.
Triple assessment: The patients were seen in the symptomatic
clinic and had a triple assessment according to local protocol.
Clinically all had a well-defined smooth lump suggestive of a
benign lump, probably a cyst, but the ultrasound in these four
patients showed atypical features and was graded as U3
(mammogram was R2). The 27 year old had internal echoes on
ultrasound and aspiration was slightly blood stained. Cytology
was reported as c3. The cyst rapidly re-accumulated in
3–4 weeks and was re-aspirated and was again blood stained.
The other three patients had an ultrasound picture suggestive of
a small pappilomatous lesion within the cyst, and guided
aspiration revealed suspicious cells. All patients underwent
excision of the lump, and the 27 year old had invasive carcinoma
and the other three patients had intracystic carcinoma.
Discussion and conclusion: Atypical features on ultrasound in
cysts need further investigation. Although cysts are very
common benign problems they would need investigation if
there were atypical features clinically or on ultrasound.
45 The amalgamation of two breast imaging units in Leeds
ME Fletcher, P Hardy
United Leeds Teaching Hospital Trust, UK
Breast Cancer Res 2004, 6(Suppl 1):P45 (DOI 10.1186/bcr864)
Within the United Leeds Teaching Hospitals Trust there are two
main breast imaging units providing symptomatic breast services.
They provide a facility for two different teams of breast surgeons
and historically operate with some differences in protocols.
There are now plans for the reconfiguration of the breast
service within the United Leeds Teaching Hospital, which is
hopefully to take place early in 2005, with the amalgamation of
the two breast imaging units on one site. Prior to this, many
changes are required for the merge to be successful.
The proposal for this proffered poster is to outline the plan for
the amalgamation of the differing protocols. We aim to identify
some of the major differences, outline the method of change in
practice through the development of new joint protocols and
determine implementation pathways
46 The four-tier system: the ups and downs of getting there
EA Keyes
Southend Hospital, Westcliff on Sea, UK
Breast Cancer Res 2004, 6(Suppl 1):P46 (DOI 10.1186/bcr865)
This poster will describe the pathway the South Essex Breast
Screening Service/Southend Breast Unit took to introduce the
radiographers’ four-tier system. This will be set out as a board
game of snakes and ladders highlighting the successes and
setbacks we encountered, and how we started, recruited staff,
trained and now use their training. Finally we show the way that
the department has grown into a learning culture with all roles
increasing their continuing professional development.
47 The road to ISO 9001:2000
DE McBurnie
York Hospital NHS Trust, UK
Breast Cancer Res 2004, 6(Suppl 1):P47 (DOI 10.1186/bcr866)
The Breast Imaging Unit at York Hospital NHS Trust is the
base for both the North Yorkshire Breast Screening Service
and the local Symptomatic Breast Imaging Service.
In compliance with National Health Service Breast Screening
Programme guidelines a quality management system has been
in place for many years, but as a unit we felt that we couldS19
improve the existing quality management system while at the
same time improving the delivery of service and care to our
clients, patients and partners.
In order to do this we evaluated different management systems
and came to the conclusion that our way forward was to try to
develop a system that would stand up to the rigorous
standards of ISO9001:2000.
It was a challenge. This poster outlines those challenges, the
hurdles, and the changes to our unit while we travelled the road
to ISO 9001:2000 accreditation.
48 Are you getting in on the Act?
EL Lightfoot
North Yorkshire Breast Screening Service, York, UK
Breast Cancer Res 2004, 6(Suppl 1):P48 (DOI 10.1186/bcr867)
The ‘Social Model’ approach to disability sees the problem as
barriers posed by society, rather than the person’s condition.
This approach empowers disabled people to challenge society
to remove these barriers, and to enable them equal opportunities.
The Disability Discrimination Act is designed to prevent
disabled people being unfairly treated. Since its introduction in
December 1996, attitudes and treatment of disabled people
have been radically altered. Part of the Act states that any
service provider has a duty to make ‘reasonable’ adjustments to
its service in order to ensure that a disabled user is not at a
disadvantage to a nondisabled user.
Since October 1999, service providers have been expected to
anticipate what help different groups of disabled people may
require in order to access their service, and to take ‘reasonable’
steps to provide the necessary help. The North Yorkshire
Breast Screening Service has undertaken an ‘inclusive
approach’ to the service it provides.
This poster aims to explore attitudes towards disability, and
demonstrate how the Disability Discrimination Act has been
successfully integrated into the working practices of North
Yorkshire Breast Screening Services.
49 Equity of access to breast and cervical screening for women with learning disabilities
B Dawes1, A Claridge-Lawrence2, M Pearce2, K Touzel3
1Chelmsford and Colchester Breast Screening Service, Colchester, UK; 2Colchester PCT Learning Disability Services, UK;
3Essex Rivers NHS Trust, Colchester, UK
Breast Cancer Res 2004, 6(Suppl 1):P49 (DOI 10.1186/bcr868)
This poster presentation pictorially depicts the evolution of a
local project that aims to enable women with learning
disabilities equity of access to breast and cervical screening. It
demonstrates that different National Health Service Trusts can
work in partnership to promote access to screening services
for women with learning disabilities and shows how networking
and joint planning can result in the development of strategies to
overcome possible barriers. The poster presentation focuses
on the facilitation of an ongoing training programme for carers
and highlights some individual projects that have been initiated
by participants. The overall theme of the project is that women
with a learning disability should receive a positive health
message, regardless of whether or not they accept or decline
screening.
50 Women’s experiences of mammography within the West Midlands Breast Screening Programme
J Baker, E O’Sullivan, O Kearins
West Midlands Cancer Intelligence Unit, Birmingham, UK
Breast Cancer Res 2004, 6(Suppl 1):P50 (DOI 10.1186/bcr869)
The West Midlands QA Reference Centre has developed a
tool to evaluate client satisfaction within breast screening. The
survey, which has been running for 4 years, measures women’s
experiences of screening and also the time between the screen
and the results.
Survey forms are supplied to breast screening services and
issued annually to women during September. To achieve
proportional representation, an average number of women
screened per month is calculated using KC62 figures and each
screening service is issued with forms for 15% of this monthly
figure.
Three-year analysis shows consistency with women attending
for the first time feeling more nervous. Consistently around
10% of women continue to question receiving an explanation
about the examination. Experiencing pain and discomfort
during mammography has increased overtime but remains
within the QA Standard. A new national information leaflet was
launched in November 2001. Prior to this, local services had
used their own leaflet. Women’s perceptions and
understanding of screening from the national leaflet were
similar to their understanding from the local leaflets.
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Overall, women continue to be satisfied with their experiences of
breast screening. Encouragingly, women are increasingly
positive about repeat participation in screening and promoting
others to attend, which reflects the high-quality service provided.
51 General practitioner (GP) practices’ perceptions of breast screening within the West Midlands
J Baker, E O’Sullivan
West Midlands Cancer Intelligence Unit, Birmingham, UK
Breast Cancer Res 2004, 6(Suppl 1):P51 (DOI 10.1186/bcr870)
The West Midlands QA Reference Centre, together with the
regional breast screening health promotion group, designed a
breast screening information sheet for use by health
professionals, to ensure that there is a consistent knowledge
and appreciation of the National Health Service Breast
Screening Programme (NHSBSP) throughout GP practices.
Together with the information sheet, a questionnaire was
issued to all GP practices in the West Midlands. The aim was
to provide the QA Reference Centre with an insight into the
ways in which breast screening is perceived in GP practices.
Of the 1019 questionnaires distributed, 387 forms were
returned, a response rate of 38%.
Overall, responses were effective in providing a good insight
and a better understanding of the way that breast screening is
perceived. The results showed most GP practices were
excellent in promoting breast screening, and several practices
worked collaboratively with Breast Screening Units in order to
meet or exceed the standards necessary for the efficient and
effective running of the NHSBSP.
It is anticipated that the introduction of the ‘Practice
Information Pack’ will encourage and facilitate the promotion of
breast screening and make primary care staff more aware of
the significance of health promotion and the importance of
encouraging breast screening in GP practices.
52 A pilot’s life for us
S Tarver, K Cronin-Cowan, ME Wheaton
Warwickshire, Solihull & Coventry Breast Screening Service, Coventry, UK
Breast Cancer Res 2004, 6(Suppl 1):P52 (DOI 10.1186/bcr871)
Following the redevelopment of the National Breast Screening
Computer System (NBSS), the Warwickshire, Solihull &
Coventry Breast Screening Service agreed to act as a pilot site
for the new software. After initially running the existing breast
screening software in parallel with the new NBSS software, the
system went ‘live’ on 26 September 2003.
The objectives of piloting the new software were as follows:
assessing the database conversion, fault/error finding,
identification of cosmetic issues, and assessment of ease of
use.
Issues were identified by the screening office staff and logged
on the pilot error log, which was submitted to Wealth
Management Systems at weekly intervals. Wealth Management
Systems discussed the log regularly with the National Project
Team and prioritised each entry on the log. A fix for each log
was then applied to the software and retested by the screening
office staff.
Piloting the new software enabled staff to have an input into
the development of the new software, gave them an insight into
software development techniques and enabled them to
improve working practices, particularly in terms of the ‘Right
Result’ procedure.
From November 2003 the new software was rolled out to the
breast screening field.
53 Monitoring radiographic data within the West Midlands National Health Service Breast
Screening Programme
J Baker, E O’Sullivan, O Kearins
West Midlands Cancer Intelligence Unit, Birmingham, UK
Breast Cancer Res 2004, 6(Suppl 1):P53 (DOI 10.1186/bcr872)
Monitoring Technical Recall/Technical Repeat is important to
ensure that the films produced by practitioners working within
breast screening are of a consistently high quality. The National
Health Service Breast Screening Programme set the standard
that at least 97% of mammograms are adequate for
radiological interpretation and ≤3% of examinations are
repeated for technical reasons.
The West Midlands Breast Screening QA Reference Centre
has developed a tool for Technical Recall/Technical Repeat
data to be collected quickly and accurately. For the period 1
April 2002–31 March 2003, 2974 (2%) women had a repeat
screen. Information is collected on the location of the original
screen (mobile or static) and the cause of the repeat.
Consistently over time the most common reason for a retake
being necessary was inadequate radiographer positioning.S21
It is important to continually monitor radiographic data as
changes may reveal equipment problems or indicate training
needs, particularly with the introduction of new staff and
assistant practitioners to facilitate programme expansion.
Date Number of women screened Number of women recalled/repeated % of women recalled/repeated
April–June 2002 35,490 907 2.6
July–September 2002 34,527 748 2.2
October–December 2002 35,882 562 1.6
January–March 2003 40,818 757 1.9
April 2002–March 2003 146,717 2974 2.0
54 Maximising the effectiveness of routine quality assurance team visits
J Bryson, O Kearins, GM Lawrence
West Midlands Cancer Intelligence Unit, Birmingham, UK
Breast Cancer Res 2004, 6(Suppl 1):P54 (DOI 10.1186/bcr873)
Routine quality assurance (QA) is an integral part of the National
Health Service Breast Screening Programme. The primary aims
of QA are to ensure the maintenance of minimum standards and
the continuing improvement of service delivery. To achieve its
objectives, QA must look at each service in its totality, while also
examining the performance of each aspect of the service. This is
attained through routine QA Team visits to each service and
also by reviewing performance data for the service as a whole.
The QA Team visits represent a dual approach to QA. The
visiting QA Team assesses the service as a whole by carrying
out an external review of data, and through internal professional
meetings. In order to maximise the effectiveness of this
intervention, the service must feel that the process is
transparent and must also have input into the way in which the
visit process is conducted. In order to obtain this input from
services, in 2003 each member of the QA Team individually
contacted their peers across the region to seek their views on
the purpose and optimum approach for QA Team visits.
The dual focality of QA Team visits will be explored, together
with the way in which breast screening professionals perceive
the QA Team visit structure and how this perception varies
between groups.
55 BreastScreen Australia’s experience taking services to rural and remote areas
J Muller
Australian Institute of Health and Welfare, Canberra, Australia and BreastScreen Australia State and Territory Programs,
Brisbane, Australia
Breast Cancer Res 2004, 6(Suppl 1):P55 (DOI 10.1186/bcr874)
The BreastScreen Australia Program commenced in 1991.
Since then a national network of breast cancer screening
services has been established including Screening and
Assessment Services, satellite, relocatable and mobile services.
In 2000–2001 the Program screened more than half a million
women. The national age-standardised participation rate for
women in the target age group 50–69 years was 56.9%. The
participation rate varied across States/Territories ranging from
46.3% in Northern Territory to 64.3% in South Australia.
A key objective of the Program is to ensure equitable
participation across all sectors of the community. The Program
has achieved a relatively high level of equity in screening
women across socioeconomic, cultural and geographically
rural/remote groups. There was no decline in participation with
decreasing socioeconomic status, with only marginal
differences for the most and least disadvantaged groups at
55.9% and 55.3%, respectively.
Participation in regional, rural and remote areas is significantly
higher than the national participation rate, ranging from 62.1%
for regional centres to 57.9% in remote areas.
This presentation will illustrate with pictures and discuss
access to breast cancer screening in Australia, specifically the
challenges of providing services across vast distances in rural
and remote Queensland.
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56 Breast cancer follow-up: a radiographer-led service
D Vaile, P Barrett-Lee
Velindre Hospital, Cardiff, UK
Breast Cancer Res 2004, 6(Suppl 1):P56 (DOI 10.1186/bcr875)
Velindre Cancer Centre treats and follows up a range of
malignancies. Historically the management of breast cancer
has been annual follow-up and, having no formal discharge
policy, clinics have become steadily more unmanageable. It
was decided to streamline the system by providing a
radiographer-led service. National Institute for Clinical
Excellence guidelines (Improving Outcomes in Breast Cancer)
provide the criteria for patients’ admission into this service.
At annual mammography, a comprehensive health
questionnaire is used to determine disease status and set
protocols exist to allow referral to the breast care team if
required.
The senior radiographer leading the service ensures that those
patients who are given a normal report receive a letter
informing them of the result, as well as arranging their next
annual mammogram. The results and any actions taken are
annotated electronically onto the hospital information system
and supplemented with a weekly forum with the breast team to
disseminate information and monitor the system.
This system has run since May 2003 resulting in patients
requiring only one hospital visit per year, while allowing more
time with the health professionals. The radiographer benefits
through role extension and better use of existing skills. The
clinics are less fraught, with more time allocated to patients.
57 Ductal carcinoma in situ (DCIS): the role of prognostic indicators in informing treatment and
reducing local recurrence
K Clements, MG Wallis, JM Macartney, GM Lawrence, MR Lee, MJ Wheaton, O Kearins, H Bishop
Sloane Project Group, West Midlands Cancer Intelligence Unit, Birmingham, UK
Breast Cancer Res 2004, 6(Suppl 1):P57 (DOI 10.1186/bcr876)
Introduction:  A retrospective study of cases of DCIS
diagnosed in the West Midlands during the period 1 April
1988–31 March 1999 was undertaken. Of the 840 cases
diagnosed, full pathology and treatment information was
available for 586 cases. Following exclusions a retrospective
radiological review was completed on 519 of these cases.
Follow-up data were attained for a maximum of 14 years and a
minimum of 3 years.
Method: Radiological characteristics were aligned with well-
accepted pathological prognostic indicators to provide a
preoperative radiological index. Analyses of operation type and
local recurrence rates were undertaken.
Results: The correlation between radiological and pathological
size was evaluated and it was noted that pathology consistently
‘underestimated’ the size of the radiologically more extensive
tumours. There was good correlation with tumour grade and
calcification type, with 53% of high grade tumours displaying
casting calcifications.
Conclusions: The dataset indicates that there may be a
possible role of preoperative radiological characteristics for
providing information previously only available postoperatively
to aid management decisions. A greater number of cases
would be required to establish this coherently. It is hoped that
the Sloane Project will be able to answer these questions.
58 Ductal carcinoma in situ (DCIS) down under: patterns of diagnosis and treatment in
BreastScreen Victoria
J Wilkinson
BreastScreen Victoria, Melbourne, Australia
Breast Cancer Res 2004, 6(Suppl 1):P58 (DOI 10.1186/bcr877)
DCIS is a contentious component of breast cancer screening
programs. Rates of diagnosis of DCIS within BreastScreen
Victoria have risen from 15% of all cancers diagnosed in 1994
to 21% in 2001. Over one-half of the DCIS diagnosed is of a
high grade.
BreastScreen Australia initially set as a standard that 10–20%
of cancers detected should be DCIS. When revised standards
were introduced in 2002, the upper limit for diagnosis was
removed.
Most surgical treatment of DCIS is by wide local excision:
73.2% in 2001. However, a greater proportion of women
diagnosed with DCIS in rural areas undergo mastectomy
(32%) compared with women in urban areas (18%).
Initially around 20% of women diagnosed with DCIS by
BreastScreen Victoria underwent axillary dissection. Following
the first reporting of nodal status in 1996, research indicated
that a majority of these procedures could be classed as
inappropriate. This had a dramatic impact on practice, andS23
since 1998 rates of axillary dissection have remained at around
10% of women diagnosed with DCIS.
While the biology of DCIS is not well understood, it is vital that
screening programs are able to explain what we do know about
DCIS in order to assist women who are making choices about
whether to screen or how to deal with a diagnosis of DCIS.
59 The usefulness of diffuse pattern of distribution in 99mTc-(V) DMSA scintimammography in the
evaluation of in situ breast carcinomas
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Breast Cancer Res 2004, 6(Suppl 1):P59 (DOI 10.1186/bcr878)
Aim: To evaluate retrospectively the diagnostic accuracy of
diffuse (V) DMSA concentration in the detection of in situ
carcinomas of the breast.
Materials and methods: A total of 71 women with mean age
62.5 years that were referred to us for suspicious breast lesions
on physical examination and/or an abnormal mammogram
underwent  99mTc-(V) DMSA scintimammography prior to any
surgical intervention. The presence of focal (V) DMSA increased
activity, as compared with surrounding tissue, was characterized
as a positive study for invasive cancer, and diffuse increased
activity was considered as suggesting noninvasive lesions. We
evaluated retrospectively this kind of distribution in relation with
the histopathology of the specimens obtained surgically.
Scintigraphic results were compared with mammograms.
Results: Breast cancer was histologically confirmed in 43/71
patients (invasive cancer in 24 patients and in situ cancer [with
or without invasive component] in 19 patients). A diffuse (V)
DMSA pattern was presented in 30 patients: in 18/19 patients
with in situ carcinomas (16 ductal in situ, two lobular in situ), in
2/24 patients with invasive cancer (microcentric ductal
carcinoma) and in 10/28 patients with benign lesions
associated with epithelial hyperplasia. The sensitivity,
specificity, accuracy, positive predictive value and negative
predictive value for in situ carcinoma were 94.7%, 76.9%,
81.7%, 60% and 97.6%, respectively.
Mammograms depicted suspicious branching or clustered
coarse granular type microcalcifications in 10/19 patients with
in situ cancer. In the remaining 12/30 patients with a diffuse
(V) DMSA pattern, only two patients had suspicious
microcalcifications (both of them with invasive cancer).
Conclusion: The diffuse pattern of (V) DMSA concentration
seems to have an excellent sensitivity in detection of in situ
breast carcinoma. In combination with a mammogram this
could provide useful preoperative information.
60 A review of interval cancers previously assessed in a mammographic screening programme
L Gallagher, J Evans, K Gower Thomas
Breast Test Wales, Cardiff, UK
Breast Cancer Res 2004, 6(Suppl 1):P60 (DOI 10.1186/bcr879)
A retrospective study was undertaken to identify cases where
assessment had been performed at the site of the interval
cancer. The study was performed for audit purposes and to
identify potential learning points to improve assessment
techniques. The interval cancers reviewed were from Breast
Test Wales (South East) between April 1997 and April 2000.
Four hundred and three intervals were identified. This
compares with 735 screen-detected cancers from the same
time period (100,211 women screened in total). Eight (2%)
had been previously assessed at the site of the interval cancer:
five had been assessed for areas of microcalcification, two for
asymmetric densities and one for distortion. From the
microcalcifications only one had undergone cytological or
histological examination.
The mean time between assessment and diagnosis of the
cancer was 27 months. It was noted that in several of the
cases there had been no change in appearance of the area that
developed the interval in several contiguous screens and/or
assessments.
We show examples of the cases, including case histories and
mammograms.
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61 Reclassification of interval cancers and implications for disclosure of audit
AE Turnbull, MJC Bagnall
Southern Derby Breast Screening Service, Derby, UK
Breast Cancer Res 2004, 6(Suppl 1):P61 (DOI 10.1186/bcr880)
Draft guidelines have been circulated on disclosure of interval
breast cancer audit, and interval cancer classification will be
modified [1].
Blinded review and reclassification of interval cancers to the
Southern Derby Breast Screening Programme from 1989 to
2002 was carried out.
Wording of the new classification places fewer cases in
‘suspicious features’ than were previously in ‘false negative’.
The results and implications for disclosure of audit are
discussed.
Reference
1. Royal College of Radiologists Breast Group Working Party: Guide-
lines on the Audit of Interval Breast Cancers and the Disclosure of
Results, 3rd draft. London: Royal College of Radiologists; July 2003.
New Old
classification classification
True 245 245
Occult 40 40
Unclassifiable 35 35
Suspicious features/false negative 20 54
Uncertain/minimal signs 130 96
Total 470 470
62 The incidence of interval breast cancers from Wirral Breast Screening Unit between 1 January
1994 and 30 June 2000
AP Tansley, G Penn, D Green, DA Berstock
Wirral Hospitals NHS Trust, Merseyside, UK
Breast Cancer Res 2004, 6(Suppl 1):P62 (DOI 10.1186/bcr881)
Objective: To report the detection rate of interval breast
cancers in the Wirral Breast Screening Unit between 1 January
1994 and 30 June 2000.
Methods: Women aged 50–64 years were invited for
screening, and data prospectively collected for both screen-
detected and interval cancer detection rates. Case notes for
interval cancers were reviewed together with two-view
mammography. True interval and false negative rates were
determined for the interval cancers. Rates of recurrence and
survival times for these cancers were also collected.
Results: Between 1 January 1994 and 30 June 2000, 82,510
women were invited to attend for screening at the Wirral Breast
Screening Unit. A total 63,159 (77%) women attended and 293
screen-detected cancers were observed. A total of 215 invasive
interval cancers were detected for the same period, 28% of
these occurred in the first 12 month interval, 37% in the next
13–24 months and 36% in the last 25–36 month interval.
Conclusions: The rate of interval cancers was similar over the
3-year period between screening rounds and the incidence of
these cancers may not be reduced by shortening the
mammographic screening period.
63 Mammographic tumour features can reliably predict the long-term outcome of women with
1–14 mm invasive breast cancer: suggestions for revision of current therapeutic practice and the
TNM classification system
L Tabar1, THH Chen2, MF Yen3, T Tot4, TH Tung2, LS Chen2, YH Chiu2, SW Duffy3, RA Smith5
1Mammography Department, Central Hospital, Falun, Sweden; 2Graduate Institute of Preventive Medicine, National Taiwan
University, Taipei, Taiwan; 3Cancer Research UK Centre For Epidemiology, Mathematics and Statistics, London, UK; 4Pathology
Department, Falun Central Hospital, Sweden; 5American Cancer Society, Atlanta, Georgia, USA
Breast Cancer Res 2004, 6(Suppl 1):P63 (DOI 10.1186/bcr882)
We studied the 24-year survival of 714 women with 1–14 mm
invasive breast cancer according to mammographic features,
including appearance of calcifications and masses. The most
common mammographic feature was a stellate lesion with no
associated calcifications (420 cases, 59%). Patients with
stellate lesions had excellent long-term survival (95%). Casting-
type calcifications were observed in 52 (7%) cases and were
significantly associated with a positive lymph node status,
poorer histological grade, and increased risk of breast cancer
death (hazard ratio = 9.19, 95% confidence interval =
4.18–20.17). Except for tumours with casting type
calcifications, all tumours less than 10 mm had excellent
survival, regardless of node status, histological grade or
treatment. For those with casting-type calcifications, survival
was poorer even with 1–9 mm tumours (72% at 20 years). For
10–14 mm tumours, 20-year survival was 52% for those withS25
casting calcifications, and 86–100% otherwise. Small invasive
cancers accompanied by casting-type calcifications have
unexpectedly poor prognosis for their size. Neoductgenesis
offers a possible explanation for the unexpectedly poor
outcome. There is a need to develop treatment protocols for
this group. After exclusion of tumours with casting-type
calcifications, the remainder have extremely good prognosis
when treated with surgery and no adjuvant therapy.
64 Screening-mammography-detected lesions undergoing benign surgical excision: review of
mammography features and preoperative needle biopsy results
DD Manuel, S Bose, DR Evans, RK Wasan, G Ralleigh, MJ Michell
King’s College Hospital NHS Trust, London, UK
Breast Cancer Res 2004, 6(Suppl 1):P64 (DOI 10.1186/bcr883)
Introduction: The aim of assessment of screen-detected
lesions is to achieve a definitive diagnosis and thereby avoid
diagnostic surgery.
Aim: To analyse the needle biopsy results and mammography
features of cases undergoing surgical excision for benign
screen-detected lesions.
Methods: A total of 155,621 women were screened by
SouthEast London Breast screening programme from April
1998 to March 2003; 8836 (5.7%) were assessed. The study
group consisted of 182 lesions that were benign on final
surgical histology (0.1% of women screened). Needle biopsy
results and mammography features were recorded on a
database.
Results: Final surgical histology of the lesion: fibrocystic
change (26%), radial scar (24%), fibroadenoma (14%),
papilloma (11%) and atypical ductal hyperplasia (7%) and
miscellaneous other (15%). The mammography features of
benign lesions excised were: well-defined mass (38%),
microcalcifications (28%), stellate distortion (28%), asymmetry
density (3%), and 4% other signs.
All 182 cases underwent biopsy, either ultrasound 14 G core
biopsy or stereo 14 G core biopsy or 11 G vacuum biopsy. Core
needle biopsy results: 13% (24/182) had inadequate, 27%
(50/182) benign, 42% (76/182) suspicious, 18% (32/182) no
biopsy performed; 21% (39/182) underwent cytology. Out of the
39 cytology aspirates performed: 41% (16/39) suspicious, 28%
(11/39) benign, 31% (12/39) inadequate.
Discussion: The most common benign lesions requiring
surgical excision are mass and microcalcifications due to
fibrocystic change and distortion due to radial scar. Forty-two
per cent (76/182) of core biopsy results showed atypia/
suspicious findings. More accurate nonoperative diagnosis
obtained by excising large volume biopsy techniques such as
vacuum biopsy should decrease the need for surgical excision
in these cases.
65 Audit of stereotactic core biopsies for microcalcification
S Chandrasekharan, R Whitney, M Scott, S Siva Nanthan, E Goes
Colchester and Chelmsford Breast Unit, Colchester, UK
Breast Cancer Res 2004, 6(Suppl 1):P65 (DOI 10.1186/bcr884)
Introduction: Microcalcifications are seen in benign and
malignant lesions. Stereotactic biopsy along with digital
equipment has made targeting these more accurate. This is a
retrospective audit of 147 core biopsies done at the
Colchester–Chelmsford screening unit.
Method: All patients who had core biopsies for assessment of
microcalcifications are included in this study and were
discussed in the multidisciplinary team meeting.
Results: Seventy patients had benign microcalcifications seen
both on X-ray and pathology. Fifty-two patients had malignant
calcifications associated with ductal carcinoma in situ (DCIS).
Table 1
Microcalcification seen Final diagnosis postsurgery
X-ray Pathology Benign (number of patients) DCIS (number of patients)
Seen in 10 patients None 7 3
Six patients not seen 2 4 (2 had B4 on core)
One patient microcalcification  DCIS
seen benign but R5 microcalcification
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Of the remaining 25 patients, five had a repeat core, which
showed benign calcification, and three were discussed at the
multidisciplinary team meeting (calcification seen on X-ray and
not on pathology) and discharged to recall in 1 year’s time.
Table 1 shows the results of the other 17 patients.
Discussion: This audit shows that 11.9% of patients had a
diagnostic operation, as the core biopsy could not give a
definitive diagnosis. The question whether this can be
improved by repeat core or mammotome cores remains to be
answered.
66 Lobular neoplasia diagnosed on stereotactic core biopsy: a management conundrum?
K Satchithananda, V Stewart, RK Wasan, N Akbar, N Dutt, DR Evans, G Ralleigh, S Bose, MJ Michell
King’s College Hospital, London, UK
Breast Cancer Res 2004, 6(Suppl 1):P66 (DOI 10.1186/bcr885)
Background: When breast core biopsy reveals lobular
neoplasia (lobular carcinoma in situ [LCIS] or atypical lobular
hyperplasia [ALH]) a management dilemma follows, as
uncertainty regarding the significance of LCIS/ALH exists. Is
this an indicator of increased risk of breast cancer or should it
be considered a marker for more serious local pathology?
Should surgical excision be undertaken in these cases?
Purpose: To correlate the finding of lobular neoplasia on
stereotactic core biopsy with final histology and thus determine
the appropriate management of such cases.
Method: The radiological and histological features of the cases
of LCIS/ALH on stereotactic core biopsies since 1994 were
reviewed and correlated with final histology.
Results: Ten cases of ALH and 12 cases of LCIS were found
from a total of 2498 (0.01%) stereotactic core biopsies.
Mammographic signs were distortion in two (9%), asymmetry
in one (4%) and microcalcification in 19 (87%). Note was
made of whether the microcalcification was in the area of
LCIS/ALH, in benign tissue alone or in both. The LCIS was
also classified histologically: classical, pleomorphic and solid
ductal carcinoma in situ (DCIS) like.
Surgical histology was available in 20 cases with one case of
invasive ductal carcinoma (5%), three invasive lobular
carcinoma (15%), three DCIS alone (15%), and one of both
invasive lobular carcinoma and DCIS (5%). The diagnosis was
upgraded (from LCIS/ALH) in eight cases (40%)
Conclusion: We recommend surgical excision should be
carried out when lobular neoplasia is diagnosed on the core
biopsy. The benign breast biopsy rate should not be
significantly affected, as these lesions are rare.
67 The relevance of clinical audit results to commissioning services
H Davis, N Richmond, GM Lawrence
West Midlands Cancer Intelligence Unit, Birmingham, UK
Breast Cancer Res 2004, 6(Suppl 1):P67 (DOI 10.1186/bcr886)
The Association of Breast Surgery at the British Association of
Surgical Oncology audit of screen-detected breast cancers is
a clinical audit that monitors diagnosis and treatment outcome
data for screen-detected breast cancer against National Health
Service (NHS) Breast Screening Programme standards. The
audit is used to identify achievement of and failure to meet the
standards by screening services and to direct appropriate
recommendations and actions.
This valuable data resource is unfamiliar to many NHS
organisations responsible for commissioning breast cancer
services such as Primary Care Trusts, Strategic Health Authorities
and Cancer Networks. To make the audit more accessible to
these organisations a Key Outcomes booklet was produced for
each West Midlands screening service, which aimed to present
the findings that are most relevant to commissioners. Results
were related to relevant government targets in the NHS Cancer
Plan (2000) and the National Institute for Clinical Excellence
publication Improving Outcomes in Breast Cancer (2002).
Production of the Key Outcomes booklet enabled the
Association of Breast Surgery at the British Association of
Surgical Oncology audit results to reach a wider, more
generalised audience, while the focus on individual screening
services allowed a more in-depth analysis of the audit results
tailored to areas of particular interest.
68 West Midlands screening histories project: methodology and use as an audit tool
J Hudson, GM Lawrence, O Kearins, J Walton, E O’Sullivan, J Baker
West Midlands Cancer Intelligence Unit, Birmingham, UK
Breast Cancer Res 2004, 6(Suppl 1):P68 (DOI 10.1186/bcr887)
The Screening Histories Project aims to assign a screening
status classification to all primary breast cancers in women
aged 50–64, who were diagnosed in the West Midlands from
1 March 1988 to 31 March 2001. The possible classificationsS27
are: screen detected, interval cancer, nonattender, lapsed
attender and diagnosed before invite.
To obtain a screening status, screen-detected cancers are
downloaded from the National Breast Screening Computer
System (NBSS), matched against the West Midlands Cancer
Intelligence Unit’s cancer registration database, and
classified as screen detected. All other eligible cases from
the cancer registration database are manually checked
against the NBSS. This involves assigning each case a
screening unit and printing individual classification forms. The
screening status is dependent upon whether the woman was
invited prior to diagnosis and whether she attended her
invitations.
The first project phase is complete and all women diagnosed
up to 31 March 1998 have been assigned a screening history.
Thirty-seven per cent of women had a screen-detected cancer,
22% were interval cancers, 14% were diagnosed before invite,
11% were nonattenders and 2% were lapsed attenders.
The dataset obtained by applying this algorithm is a valuable
resource for the evaluation of breast screening in the West
Midlands.
69 The value of arbitration in a breast screening programme
AM Gilchrist
South East Scotland Breast Screening Programme, Edinburgh, UK
Breast Cancer Res 2004, 6(Suppl 1):P69 (DOI 10.1186/bcr888)
Double reading with arbitration is identified as the best pattern
to detect the maximum number of cancers. The balance
between cancer detection and recall rates must be maintained
while acknowledging the steep learning curve for new film
readers in the National Health Service Breast Screening
Programme. A recent study highlighted these findings [1].
We present the data on 761 arbitrated cases that support this
study. Eighty per cent of first-read recalls and 57% of second-
read recalls were overruled. Following review, 96% of arbitrated
cases were returned to routine screen. Of the remaining 4%
(n = 27), 10 were cancers and two were radial scars.
No particular pattern was identified among readers for hits or
misses. Arbitration provides a group of cases where
interpretation is difficult. Analysis of first reader over recall
should increase specificity. Reviewing arbitrated cancers is a
valuable learning exercise. Identifying specific weaknesses,
strengths and arbitrator recall rates allows us to maximise the
benefits of different working practices.
Can the National Health Service Breast Screening Programme
afford not to double read screening mammograms?
Reference
1. Liston JC, Dall BJG: Clin Radiol 2003, 58:474-477.
70 Assessment clinics at ‘Avon Breast Screening Unit’: what has changed in 5 years?
S Chakrabarthi, A Jones, E Kutt
Avon Breast Screening Unit, Bristol, UK
Breast Cancer Res 2004, 6(Suppl 1):P70 (DOI 10.1186/bcr889)
Introduction: There have been many changes in the breast
screening programme over the past few years. The most
significant locally is probably the introduction of two-view
mammography at all rounds since April 2003. We also
introduced a formal weekly arbitration meeting in December
2001 where borderline patients are discussed and a collective
decision taken regarding the need for assessment. All those
who read screening films attend this meeting.
We perceived there had been a change in outcomes,
procedures performed in the clinic, and overall pick-up rate.
This could be an indicator of change at a national level. Hence,
this study to compare the assessment clinics was undertaken.
Aims and objectives: To compare the assessment clinics
conducted in 1998 with those of 2003.
Materials and methods: Retrospective analysis of films and
notes of all patients assessed during September and October
1998 and 2003.
Results:
Conclusion: More patients were assessed sooner in 1998.
However, more complex procedures and more procedures
overall were performed in 2003. The cancer pick-up rate
doubled in 2003.
1998 2003
Number of patients assessed 192 188
Assessed within 3/52 weeks of screening 87% 41%
Surgical referral 30 (15.5%) 53 (28%)
Procedures in clinic 38 (20%) 53 (28%)
Final malignant diagnosis 20 (10%) 40 (21%)
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71 Maintaining standards through coordinated follow-up of Quality Assurance (QA) Team visit
recommendations
RA Davies, O Kearins, GM Lawrence
West Midlands Cancer Intelligence Unit, Birmingham, UK
Breast Cancer Res 2004, 6(Suppl 1):P71 (DOI 10.1186/bcr890)
The Commission for Health Improvement report into the West
London Breast Screening Service recommended that a formal
structure for the follow-up of recommendations made at QA
Team visits is implemented.
In the West Midlands, breast screening services are visited
every 3 years as part of a rolling programme. Following a QA
Team visit, a service can expect 3-month and longer term
recommendations, and on rare occasions immediate recom-
mendations concerning areas that require improvement.
Written conformation of immediate and 3-month recommenda-
tion is issued to the service within 1 week of the visit. Longer
term recommendations are included in the written QA Team
visit report, which is issued within 4 weeks of the QA Team
visit. A detailed process has been put in place that tracks the
receipt of recommendations within the required timescales,
highlights nonresponses and distributes the recommendations
to the relevant QA Team members for classification and further
instruction.
One-year post visit, all recommendations must be completed to
the satisfaction of the visiting QA Team. At this point a formal
document is compiled that details the recommendations and
responses from the breast screening service. This document is
then sent to the host trust chief executive, director of breast
screening and lead primary care trust coordinator to sign,
indicating that the resulting actions have been incorporated
fully into the service’s policies and procedures. In the event of
noncompliance, separate reporting mechanisms have been
introduced.
72 Prospective estimation of rates of change in mammographic parenchymal patterns: influence of
age and of hormone replacement (HRT) therapy
JP Myles1, T Salminen2, SW Duffy1, TC Prevost3, NE Day4, M Hakama2
1Cancer Research UK Centre for Epidemiology, Mathematics and Statistics, London, UK; 2Tampere School of Public Health,
Finland; 3MRC Biostatistics Unit, Cambridge, UK; 4Strangeways Research Laboratory, Cambridge, UK
Breast Cancer Res 2004, 6(Suppl 1):P72 (DOI 10.1186/bcr891)
The objective of the study described in this presentation was
to assess the effect of age, breast size and use of HRT on the
rate of change of mammographic parenchymal patterns, and
the effect of age on the probability of misclassification
between patterns. It was designed as a longitudinal study of
the members of the treatment arm of a nonrandomized
screening trial. A model was fitted to the data comprising the
observed Wolfe patterns on each woman, with age and breast
size as predictors of breast density at first screen, age and
HRT use as predictors of change in density at future screens,
and age as a predictor of misclassification of true density
between favourable (nondense) and unfavourable (dense)
patterns (according to the Wolfe classification). The
probability of being in a nondense, favourable state increases
with age, as does the rate of change from dense to nondense
patterns. These results are consistent with previous work. The
probability of nondense patterns and the rate of change to
nondense patterns are reduced with HRT use. Errors of
classification are relatively rare, but are dependent on the age
of the subject.
73 The effect of age and breast density on the sensitivity of mammography
AM Kavanagh1, GB Byrnes2, J Hopper4, GG Giles3, DM Gertig4, JN Cawson2, G Marr3
1La Trobe University, Melbourne, Australia; 2St Vincents BreastScreen, Melbourne, Australia; 3Cancer Council of Victoria,
Melbourne, Australia; 4University of Melbourne, Australia
Breast Cancer Res 2004, 6(Suppl 1):P73 (DOI 10.1186/bcr892)
This study examines the extent to which differences in
sensitivity by age can be attributed to variations in breast
density using a reliable, computer-assisted, continuous
measure of per cent breast density.
We included women aged 40–79 years, not using hormone
replacement therapy, who attended BreastScreen Victoria for
first-round screening mammography in 1994 and 1995 (1002
breast cancers) and for subsequent-round screening (381
breast cancers) in 1995 and 1996. True positive cancers were
invasive breast cancers diagnosed at screening and false
negative cancers were cancers diagnosed within 24 months of
a negative screening examination.
The effect of age (years) on the risk of having a false negative
cancer (first round: odds ratio [OR] = 0.94, 95% confidence
interval [CI] = 0.92–0.96; and second round: OR = 0.93, 95%
CI = 0.90–0.96) was modestly attenuated when adjustment
was made for mammographic density (first round: OR = 0.96,
95% CI = 0.94–0.98; and second round: OR = 0.94, 95% CIS29
= 0.91–0.98). Adjusting for family history, symptom status, and
tumour characteristics (grade, size and morphology) did not
influence the estimates of the effects of age.
The study confirms that younger women have lower sensitivity
but demonstrates that the lower sensitivity cannot be
completely explained by variations in breast density.
74 Can the sensitivity/specificity of reporting indeterminate breast calcifications be improved?
J Clarke
South East Scotland Breast Screening Programme, Edinburgh, UK
Breast Cancer Res 2004, 6(Suppl 1):P74 (DOI 10.1186/bcr893)
Aim: To assess whether the sensitivity and specificity of the
current grading system for screen-detected mammographic
indeterminate microcalcification can be improved.
Materials and methods: One hundred and twenty-seven
screen-detected indeterminate (R3) microcalcifications were
retrospectively and independently assessed by six experienced
screening radiologists. Information was gathered in relation to
specific features of the calcification and their level of suspicion
graded 1–4. An informed decision was requested as to
outcome. These outcomes were then related to final
histological diagnosis.
Results: Of the 127 cases, 32 were histologically malignant
and 95 benign. In only 19 cases of R3 microcalcification did all
radiologists agree. There was significant interobserver
variation. Reader sensitivity was 53% (median, range 31–69%)
and specificity was 72% (median, range 57–88%). Cut-off
points for features graded 3 or greater gave a change in
sensitivity to 64% (median, range 34–88%) and specificity
55% (median, range 34–82%).
Conclusion: Radiological interpretation of indeterminate
microcalcification lesions is difficult. Significant variation was
identified between individual radiologists. Attention to specific
features allows some increase in sensitivity but not enough to
obviate biopsy.
75 The value of three-dimensional (3D) ultrasound examination in the assessment of small breast
tumours
K Mlosek1, M Wysocki2, JG Sieluzycka1, W Jakubowski1, ES Pienkowska3
1AM, Warsaw, Poland; 2CMKP, Warsaw, Poland; 3WIM, Warsaw, Poland
Breast Cancer Res 2004, 6(Suppl 1):P75 (DOI 10.1186/bcr894)
Aim: The purpose of this study was to determine the value of
3D ultrasound examination in the diagnostic procedure of the
small breast tumours.
Materials and methods: A total 182 small breast tumours
were analysed in 146 patients aged ranging from 17 to 72
years. All patients had undergone two-dimensional (2D)
ultrasound examination, 3D ultrasound examination and
ultrasound-guided fine needle aspiration biopsy. 2D ultrasound
examination was performed with seven to 12 linear probes. 3D
ultrasound examination was performed with a linear scanner,
6–12 MHz (Voluson 730; KretzTechnik, Zipf, Austria). Fine
needle aspiration biopsy was performed under ultrasound
biopsy, method free hand.
Results: The study group consisted of 182 small breast
tumours. The 2D ultrasound examination demonstrated dense
cysts (9.34%), fibroadenomas (36.81%), and probable
carcinomas (53.85%). 3D ultrasound examination showed
dense cysts (48.9%), fibroadenomas (34.07%), and probable
carcinomas (17.03%). The cytological results were benign
(88.46%) and malignant (11.54%).
Conclusion: 3D ultrasound examination improves small breast
tumour diagnostics.
76 Design of a retrospective study of computer-aided detection in mammographic screening:
Computer Aided Detection Evaluation Trial
FJ Gilbert1, S Astley Theodossiadis2, MA McGee3, MCG Gillan1, H Deans3, K Duncan3, G Iyengar3, C Boggis2, M Wilson2, 
U Beetles2, A Jain2, P Griffiths2, SW Duffy4
1Department of Radiology, University of Aberdeen, UK; 2Nightingale Centre, Manchester, UK; 3Breast Screening Centre,
Aberdeen, UK; 4CR-UK, Wolfson Institute of Preventative Medicine, London, UK
Breast Cancer Res 2004, 6(Suppl 1):P76 (DOI 10.1186/bcr895)
The National Health Service Breast Screening Programme is an
intensive consumer of radiology time. In principle, screening
mammograms must be double read, and this puts considerable
strain on human resources. The possibility of using single reading
assisted by computer-aided detection rather than double reading
is therefore an important research issue. Before expending
considerable resources on a prospective randomised trial, we
design a retrospective study involving re-reading of previously
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double-read mammograms (Computer Aided Detection
Evaluation Trial). This was an equivalence, powered to assess
whether the sensitivity of a single human reader with the R2
system of computer-aided detection was at least no worse than
10% less sensitive than the previous two human readers. Various
complications had to be taken account of in the design:
• power calculations suggested we needed 15,000
mammograms to give the required number of cancers, but
funding was only available to re-read 10,000;
• the ethical problem of potential de novo discovery of
previously missed cancer;
• a limited period of free availability of the R2 system; and
• a need to avoid previous readers re-reading the same
mammograms.
Design strategies to cope with these are described in this
poster.
77 Quality assurance of routinely collected data in the Computer Aided Detection Evaluation Trial
MA McGee1, FJ Gilbert2, SW Duffy1, SM Astley3, P Griffiths3, C Boggis3
1Cancer Research UK, London, UK; 2University of Aberdeen, UK; 3University of Manchester, UK
Breast Cancer Res 2004, 6(Suppl 1):P77 (DOI 10.1186/bcr896)
A study may only be feasible when routinely collected data
(RCD) are used to identify participants. RCD from one centre
in a retrospective study of computer-aided detection (CAD) in
breast screening are considered. Double-read mammograms
were re-read by a different reader using CAD (R2
ImageChecker®) and the cancer detection and recall rates
were compared.
Subjects attended routine screening during 1996 and were
aged 50 years or over. Among RCD subjects, 11,947 (92.5%)
were eligible. From the study sample (n = 5037), a subsample
of 650 (13%) subjects was examined.
Previous attendance was incorrect in all four subjects with
earlier screening at a different centre. The reader was correctly
recorded in all but one subject where it was missing on the
paper copy. Whether a subject was recalled for further
examination was correct for all subjects; however, single-reader
recall, when recall was requested by only one radiologist, was
incorrect in 22 (3%) cases; each was among the 53 (8%)
recalls showing 42% were incorrect (95% confidence interval,
28–56%).
Single-reader recall was unreliable and previous attendance
did not have sufficient detail to report the whether a screen
was prevalent. Both were checked throughout the study.
Issues raised when using RCD are discussed.
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41 Compression/encryption technology applied to Dicom/digitised mammography
RW Grant, MJ Alsewan, MC Devlin
Victoria Breast Screening Centre, Romford, UK
Breast Cancer Res 2004, 6(Suppl 1):P41 (DOI 10.1186/bcr860)
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